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Interest in linear peptides and peptidomimetics experienced rapid growth within the 
pharmaceutical industry due to their ability to disrupt protein-protein interactions; and 
their ability to modulate protein function by allosteric regulation and competitive 
binding. However, many linear peptides that show therapeutic potential cannot be 
readily developed into bioavailable pharmaceuticals due to their poor lipophilicity and 
protease stability; and their unpredictable secondary structures. Macrocyclic peptides 
show increased lipophilicity and protease stability; and their constrained secondary 
structures often lead to improved target binding affinity and selectivity. Consequently, 
there has been a resurgence of interest within the pharmaceutical industry towards 
peptide based therapeutics and increased research towards novel peptide 
macrocyclisation strategies. 
 
Progress towards a novel solid-phase peptide macrocyclisation strategy based on the 
inverse electron demand Diels-Alder reaction of 1,2,4,5-tetrazines is reported in this 
thesis. The solid-phase oxidation activation peptide macrocyclisation strategy uses the 
in situ oxidation of a dihydro-1,2,4,5-tetrazine to trigger the inverse electron demand 
Diels-Alder reaction of a 1,2,4,5,-tetrazine and therefore peptide macrocyclisation. 
Also, the solid-phase oxidation activation peptide macrocyclisation strategy enables 
selective late stage incorporation of the dihydro-1,2,4,5-tetrazine moiety onto the 
peptide backbone in the presence of a dienophile. A successful proof of concept in situ 
oxidation and inverse electron demand Diels-Alder reaction of a dihydro-1,2,4,5-
tetrazine was achieved. However, the poor stability of a strained dienophile towards 
an oxidant was also highlighted. To overcome this problem a library of alternative 
oxidants and a library of unstrained dienophiles were screened to successfully optimise 
the proof of concept in situ oxidation and inverse electron demand Diels-Alder reaction 
of a dihydro-1,2,4,5-tetrazine. The optimised in situ oxidation and inverse electron 
demand Diels-Alder reaction of a dihydro-1,2,4,5-tetrazine was successfully 
transferred onto solid-phase using resin-bound dienophiles. However, attempts to 
synthesise resin-bound dihydro-1,2,4,5-tetrazine derivatised amino acids were 
unsuccessful. Therefore, an alternative dihydro-1,2,4,5-tetrazine was selected for 
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A linear peptide is a straight molecule which consists of a short chain of amino acids 
bound together by chemical bonds. Interest in linear peptides experienced rapid growth 
within the pharmaceutical industry due to their ability to target both non-traditional 
and traditional pharmaceutical targets. However, many linear peptides which show 
therapeutic potential do not reach the market due to their inability to cross barriers and 
their rapid decomposition within the body. 
 
A macrocyclic peptide is a circular peptide that is formed when a chemical bond links 
two amino acids within a linear peptide together. Macrocyclic peptides can overcome 
the problems associated with linear peptides whilst showing additional desirable 
properties for a pharmaceutical molecule. Consequently, there has been a resurgence 
of interest within the pharmaceutical industry towards peptide based therapeutics and 
increased research towards novel peptide macrocyclisation strategies. Progress 
towards a novel peptide macrocyclisation strategy is reported in this thesis.
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Chapter 1. Introduction 
 
1.1. Peptide based Therapeutics 
 
Interest in linear peptides and peptidomimetics experienced rapid growth within the 
pharmaceutical industry due to their ability to disrupt protein-protein interactions; and 
modulate protein function by allosteric regulation and competitive binding.1,2 Also, 
linear peptides bridge the gap between small molecule and biologic therapeutics which 
was a previously unexplored region of chemical space for pharmaceutical molecules. 
Furthermore, the amino acid building blocks of linear peptides provide chemical 
diversity and non-toxic metabolites upon proteolysis of a linear peptide. However, 
many linear peptides that show therapeutic potential cannot be readily developed into 
bioavailable pharmaceuticals due to their poor lipophilicity and protease stability; and 
their unpredictable secondary structures. Macrocyclic peptides show increased 
lipophilicity and protease stability; and their constrained secondary structures often 
lead to improved target binding affinity and selectivity. Consequently, there has been 
a resurgence of interest within the pharmaceutical industry towards peptide based 
therapeutics and increased research towards novel peptide macrocyclisation strategies. 
 
1.2. Synthesis of Macrocyclic Peptides 
 
General strategies for the synthesis of macrocyclic peptides include head-to-side chain, 
head-to-tail, side chain-to-side chain or side chain-to-tail peptide macrocyclisations 
(Figure 1).3 The macrocyclic peptide that is synthesised depends upon the functional 
groups present on the peptide backbone and the peptide macrocyclisation strategy used 
for the synthesis of that macrocyclic peptide. Head-to-side chain, head-to-tail, side 
chain-to-side chain or side chain-to-tail lactamisation; head-to-side chain or side 
chain-to-side chain lactonisation; and side chain-to-side chain disulfide bridge 
formation are examples of peptide macrocyclisation strategies which use standard 





Figure 1. General strategies for the synthesis of macrocyclic peptides. 
 
Side chain-to-tail peptide macrocyclisations of leucine rich linear tetra-, penta-, hexa- 
and heptapeptides; and ligands of Vascular Endothelial Growth Factor Receptor 1 have 
been achieved using the solid-phase copper(I) catalysed 1,3-dipolar cycloaddition of 
an alkyne with an azide peptide macrocyclisation strategy (Scheme 1A).4-7 However, 
depending on the linear peptides length and sequence competing intermolecular 
reactions can give rise to side products during peptide macrocyclisations using the 
solid-phase copper(I) catalysed 1,3-dipolar cycloaddition of an alkyne with an azide 
peptide macrocyclisation strategy.8 The solid-phase copper(I) catalysed 1,3-dipolar 
cycloaddition of an alkyne with an azide peptide macrocyclisation strategy uses N3-
Aaa-OH 1 and commercially available L-C-propargylglycine to enable peptide 
macrocyclisation. The established synthesis of N3-Aaa-OH 1 is the copper(I) catalysed 
diazo transfer of trifluoromethanesulfonate azide 2 with H2N-Aaa-OH in the presence 




Scheme 1A. Solid-phase copper(I) catalysed 1,3-dipolar cycloaddition of an alkyne with an azide 




Side chain-to-side chain peptide macrocyclisations have been achieved using the solid-
phase ruthenium(IV) catalysed ring closing alkene metathesis peptide 
macrocyclisation strategy (Scheme 2).11-13 However, incomplete peptide 
macrocyclisation can be observed during solid-phase ruthenium(IV) catalysed ring 
closing alkene metathesis peptide macrocyclisation. The solid-phase ruthenium(IV) 
catalysed ring closing alkene metathesis peptide macrocyclisation strategy uses 




Scheme 2. Solid-phase ruthenium(IV) catalysed ring closing alkene metathesis peptide 
macrocyclisation strategy.13 
 
Many other examples of peptide macrocyclisation strategies which use non-
proteinogenic amino acids have been reported within the literature.3 However, each 
peptide macrocyclisation strategy reported within the literature has associated 
limitations. Therefore, further peptide macrocyclisation strategies which are 
complimentary to the existing peptide macrocyclisation strategies are required. A 
peptide macrocyclisation strategy based on the inverse electron demand Diels-Alder 




1,2,4,5-Tetrazines are six-membered azaaromatic compounds which contain two sp2 
hybridised carbon atoms and four sp2 hybridised nitrogen atoms and can be either 
symmetrically or unsymmetrically (di)substituted (Figure 2). A diverse range of 
symmetrically and unsymmetrically (di)substituted 1,2,4,5-tetrazines have been 
reported within the literature with acyl, alkenyl, alkyl, alkynyl, amide, aryl, ester, 
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halogen, heteroaryl and heteroatom substituents.16-25 The first reported synthesis of a 
disubstituted 1,2,4,5-tetrazine was in 1893 whilst the first reported synthesis of 1,2,4,5-




Figure 2. 1,2,4,5-Tetrazines. 
 
Due to the presence of four electronegative nitrogen atoms 1,2,4,5-tetrazines can be 
considered as the most electron deficient parent azaaromatic compound as both 
pentazine and hexazine are unstable at ambient temperature (rt).27 The electron 
deficient nature of 1,2,4,5-tetrazines enables them to be reduced at high potentials and 
leads to a low-lying π* molecular orbital.28 The low-lying π* molecular orbital gives 
rise to their characteristic purple or red colours due to a weak n-π* transition in the 
visible region of the electromagnetic spectrum.29 The n-π* transition of 1,2,4,5-
tetrazines is weakly dependent upon the nature of the substituents.30 Some 1,2,4,5-
tetrazines are known to be fluorescent although initially high quantum yields of 
decomposition were observed upon irradiation.31,32 The fluorescent properties of 
1,2,4,5-tetrazines are dependent upon the size and nature of the substituents.33,34 
 
Since the first reported syntheses of 1,2,4,5-tetrazines they have been investigated in 
numerous fields of research. The coordination chemistry of 1,2,4,5-tetrazines has been 
researched due to their metal-to-metal bridging capacity which can be exploited in 
functional supramolecular structures whilst the coordination chemistry; and 
electrochemistry and photochemistry of 1,2,4,5-tetrazines has been exploited in 
catalysis.35-37 The electrochemistry and photochemistry of 1,2,4,5-tetrazines has been 
researched to enable the development of novel functional materials and molecules with 
potential applications in electronics, energy storage, nonlinear optics and 
sensors.38Also, 1,2,4,5-tetrazines have been researched as high-nitrogen energetic 
materials and have been used in explosives, fire retardants, propellants and 
pyrotechnics due to their high nitrogen content, heats of formation and thermal 
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stability.39-42 Furthermore, the biological activity of 1,2,4,5-tetrazines has been 
researched and they have been used in crop protection and show potential as 
pharmaceutical molecules.43,44 
 
1.3.1. Synthesis of 1,2,4,5-Tetrazines 
 
There are no synthetic routes which enable the direct synthesis of the 1,2,4,5-tetrazine 
core. Therefore, all synthetic routes towards symmetrically disubstituted tetrazine 3 
must synthesise and subsequently oxidise symmetrically disubstituted 
tetrahydrotetrazine 4 or symmetrically disubstituted dihydrotetrazine 5 (Scheme 3). 
Additional 1,2,4,5-tetrazines can be synthesised by the modification or substitution of 




Scheme 3. Synthesis of symmetrically disubstituted tetrazine 3. 
 
The established synthesis of diaryl 1,2,4,5-tetrazines is the Pinner synthesis of 
disubstituted 1,2,4,5-tetrazines (Scheme 4A).21 The reaction of nitrile 6 with hydrazine 
7 and subsequent oxidation of symmetrically disubstituted dihydrotetrazine 5 gives 
symmetrically disubstituted tetrazine 3. The reaction of nitriles 8 and 9 with hydrazine 
7 and subsequent oxidation of the resulting unsymmetrically disubstituted dihydro-
1,2,4,5-tetrazine gives unsymmetrically disubstituted tetrazine 10 (Scheme 4B). 
However, the Pinner synthesis of unsymmetrically disubstituted 1,2,4,5-tetrazines 
only gives unsymmetrically disubstituted tetrazine 10 at 50 % theoretical yield due to 
side reactions giving symmetrically disubstituted tetrazines 11 and 12 at 25 % 
theoretical yield respectively. An additional limitation of the Pinner synthesis of 
disubstituted 1,2,4,5-tetrazines is the poor tolerance to alkyl nitriles when attempting 
to synthesise disubstituted 1,2,4,5-tetrazines with alkyl substituents.45 Also, the 
formation of disubstituted 1,2,4-triazole-4-amine side products has been reported 





Scheme 4A. Pinner synthesis of symmetrically disubstituted tetrazine 3.21 Scheme 4B. Pinner 
synthesis of unsymmetrically disubstituted tetrazine 10. 
 
No mechanism has been proposed within the literature for the Pinner synthesis of 
disubstituted 1,2,4,5-tetrazines. However, a mechanism has been proposed within the 
literature but not corroborated by any mechanistic studies for the sulfur-promoted 
Pinner synthesis of disubstituted 1,2,4,5-tetrazines (Scheme 5).48,49 The addition of 
sulfur to hydrazine 7 and subsequent nucleophilic addition of nitrile 6 to thiol 
hydrazine 13 was proposed to give thiol amidrazone 14. Successive nucleophilic 
addition of nitrile 6 to thiol amidrazone 14 and subsequent elimination of hydrogen 
sulfide from thiol dicarboximidamide 15 was proposed to give diimine azo 16. The 
ring closure of diimine azo 16 and subsequent oxidation of the resulting symmetrically 
disubstituted dihydro-1,2,4,5-tetrazine was proposed to give symmetrically 
disubstituted tetrazine 3. Evidence for the proposed mechanism was given by a colour 
change upon the addition of sulfur to hydrazine 7 and the elimination of hydrogen 






Scheme 5. Proposed mechanism for the sulfur-promoted Pinner synthesis of symmetrically 
disubstituted tetrazine 3.49 
 
The established synthesis of disubstituted 1,2,4,5-tetrazines with alkyl substituents is 
the Lewis acid catalysed Pinner synthesis of disubstituted 1,2,4,5-tetrazines (Scheme 
6A).18 A limitation of the Lewis acid catalysed Pinner synthesis of disubstituted 
1,2,4,5-tetrazines is the requirement to use anhydrous hydrazine which has limited 
commercial availability due to its use as rocket fuel. No mechanism has been proposed 
within the literature for the Lewis acid catalysed Pinner synthesis of disubstituted 
1,2,4,5-tetrazines. However, it was proposed in the literature that the Lewis acid might 
promote the nucleophilic addition of nitrile 6 to hydrazine 7. It was also reported in 
the literature that Lewis acids significantly improve the isolated yields of the modified 
Pinner synthesis of unsymmetrical aryl 1,2,4,5-tetrazines (Scheme 6B).50 The reaction 
of aryl nitrile 17 with hydrazine 7 and carboximidamide salt 18 and subsequent 
oxidation of the resulting unsymmetrical aryl dihydro-1,2,4,5-tetrazine gives 




Scheme 6A. Lewis acid catalysed Pinner synthesis of symmetrically disubstituted tetrazine 3.18 
Scheme 6B. Modified Pinner synthesis of unsymmetrical aryl tetrazine 19.50 
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The first synthetic route for the synthesis of a disubstituted 1,2,4,5-tetrazine with 
alkenyl substituents was developed to enable the synthesis of diethenyl-1,2,4,5-
tetrazine.17 However, the in situ elimination and Heck cross-coupling reaction of 
unsymmetrical methanesulfonyl protected tetrazine 20 with bromoaryl 21 to give 
unsymmetrical alkenyl tetrazine 22 enables the synthesis of disubstituted 1,2,4,5-




Scheme 7. Synthesis of unsymmetrical alkenyl tetrazine 22.51 
 
The electron deficient nature of 1,2,4,5-tetrazines enables them to undergo 
nucleophilic aromatic substitution (SNAr) when suitable leaving groups are present on 
the 1,2,4,5-tetrazine core (Scheme 8A). The SNAr of symmetrically disubstituted 
tetrazine 23 with an appropriate nucleophile gives unsymmetrically disubstituted 
tetrazine 24 or symmetrically disubstituted tetrazine 3. Further SNAr of 
unsymmetrically disubstituted tetrazine 25 with an appropriate nucleophile gives 
unsymmetrically substituted tetrazine 10 (Scheme 8B). The outcome of the SNAr of 
1,2,4,5-terazines is dependent upon the nature of the nucleophile and the substituents 
on the 1,2,4,5-tetrazine core.52 The most commonly used 1,2,4,5-tetrazines for SNAr 
chemistry are dichloro-1,2,4,5-tetrazine, bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-
tetrazine and bis(methylsulfanyl)-1,2,4,5-tetrazine.23-25 Heteroatom-based 
nucleophiles are the most commonly used nucleophiles for the SNAr of 1,2,4,5-
tetrazines whilst carbon-based nucleophiles give azaphilic addition, metal 
complexation or 1,2,4,5-tetrazine reduction.53,54 However, the SNAr of 1,2,4,5-
tetrazines with a limited number of carbon-based nucleophiles has been reported 
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within the literature.38,55,56 Also, the SNAr of bis(3,5-dimethyl-1H-pyrazol-1-yl)-
1,2,4,5-tetrazine with resin-bound cysteine residues has been reported within the 
literature to give macrocyclic peptides which enabled investigations into the early 




Scheme 8A. Synthesis of unsymmetrically disubstituted tetrazine 24 or symmetrically disubstituted 
tetrazine 3. Scheme 8B. Synthesis of unsymmetrically disubstituted tetrazine 10. 
 
The established synthesis of unsymmetrically disubstituted 1,2,4,5-tetrazines with 
alkynyl substituents is the Sonogashira cross-coupling reaction of amino chloro 
tetrazine 26 with terminal alkyne 27 to give amino alkynyl tetrazine 28 (Scheme 9A).19 
The palladium(II) catalysed cross-coupling reactions of amino thioester tetrazine 29 
with boronic acid 30 or organotin derivative 31 to give amino aryl tetrazine 32 have 
also been demonstrated within the literature (Scheme 9B).58 The major limitation of 
the cross-coupling reactions used for the synthesis of unsymmetrically disubstituted 
1,2,4,5-tetrazines with alkynyl substituents is the requirement to use unsymmetrically 
disubstituted 1,2,4,5-tetrazines with tertiary amine substituents. Unsymmetrically 
disubstituted 1,2,4,5-tetrazines with primary or secondary amine substituents did not 
undergo Sonogashira cross-coupling whilst more electron deficient unsymmetrically 






Scheme 9A. Synthesis of amino alkynyl tetrazine 28.19 Scheme 9B. Synthesis of amino aryl tetrazine 
32.58 
 
The established synthesis of symmetrical diacyl 1,2,4,5-tetrazines is the base promoted 
dimerisation of diazo ketone 33 and subsequent oxidation of the resulting symmetrical 




Scheme 10. Synthesis of symmetrical diacyl tetrazine 34.16 
 
1.3.2. Inverse Electron Demand Diels-Alder Reaction of 1,2,4,5-Tetrazines 
 
The Diels-Alder reaction is a [4+2] cycloaddition reaction between a diene and a 
dienophile which is dictated by the highest occupied molecular orbital (HOMO) of the 
diene and the lowest unoccupied molecular orbital (LUMO) of the dienophile (Figure 
3A). Dienes with electron donating groups and dienophiles with electron withdrawing 
groups increase the rate of reaction of the Diels-Alder reaction by decreasing the 
HOMOdiene-LUMOdienophile energy gap. The electron deficient nature of 1,2,4,5-
tetrazines enables them to act as azadienes in iedDA reactions.14,15 The iedDA reaction 
is dictated by the HOMOdienophile and the LUMOdiene (Figure 3B). Dienes with electron 
withdrawing groups and dienophiles with electron donating groups increase the rate of 






Figure 3A. Diels-Alder reaction molecular orbital diagram. Figure 3B. iedDA reaction molecular 
orbital diagram. 
 
A mechanism was proposed within the literature for the iedDA reaction of 1,2,4,5-
tetrazines (Scheme 11A).14,59 The [4+2] cycloaddition of symmetrically disubstituted 
tetrazine 11 with symmetrically disubstituted alkene 35 gives bicyclic adduct 36. 
Successive retro-[4+2] cycloaddition of bicyclic adduct 36 and subsequent 
tautomerisation of symmetrically tetrasubstituted dihydropyridazine 37 gives 
symmetrically tetrasubstituted dihydropyridazine 38.60 The oxidation of 
symmetrically tetrasubstituted dihydropyridazine 38 gives symmetrically 
tetrasubstituted pyridazine 39. The [4+2] cycloaddition of symmetrically disubstituted 
tetrazine 11 with symmetrically disubstituted alkyne 40 gives symmetrically 
tetrasubstituted pyridazine 39 after successive retro-[4+2] cycloaddition of bicyclic 
adduct 41 (Scheme 11B). The rate limiting step of the iedDA reaction of 1,2,4,5-
tetrazines is the initial [4+2] cycloaddition with the dienophile.61 Therefore, iedDA 
reactions of 1,2,4,5-tetrazines are characterised by second order reaction kinetics. 
Evidence for a concerted [4+2] cycloaddition is given by large negative entropies of 
activation and minimal solvent effects on the iedDA reaction of 1,2,4,5-tetrazines.62 
Further evidence for a concerted [4+2] cycloaddition was given by an ab initio 
quantum mechanical investigation into the iedDA reactions of 1,2,4,5-tetrazines.63 Ab 
initio quantum mechanical calculations on the iedDA reactions of 1,2,4,5-tetrazines 





Scheme 11A. Mechanism of the iedDA reaction of symmetrically disubstituted tetrazine 11 with 
symmetrically disubstituted alkene 35. Scheme 11B. Mechanism of the iedDA reaction of 
symmetrically disubstituted tetrazine 11 with symmetrically disubstituted alkyne 40. 
 
Regioselective iedDA reactions of electronically biased 1,2,4,5-tetrazines with 
electronically biased dienophiles in solution- and on solid-phase have been reported 
within the literature (Scheme 12).65-68 The iedDA reaction of electronically biased 
tetrazine 42 with electronically biased alkene 43 and subsequent elimination of the 
leaving group from the resulting unsymmetrically tetrasubstituted dihydropyridazine 
gives unsymmetrically tetrasubstituted pyridazine 44. However, iedDA reactions of 
electronically biased 1,2,4,5-tetrazines with electronically unbiased alkenes have been 
reported to give a mixture of diastereomeric and regioisomeric dihydropyridazines 
(Appendix 1).69 The oxidation of diasteromeric dihydropyridazines gives 
diastereomerically pure pyridazines due to the aromatic and therefore planar 












Scheme 12. iedDA reaction of electronically biased tetrazine 42 with electronically biased alkene 43. 
 
The iedDA reaction of 1,2,4,5-tetrazines undergoes a dramatic increase in the rate of 
reaction when conducted in hydrous solvents due to hydrogen bonding and 
hydrophobic effects which stabilise the initial [4+2] cycloaddition transition state.70-74 
The increased rate of reaction observed in hydrous solvents and the bioorthogonality 
of the iedDA reaction of 1,2,4,5-tetrazines enables it to be used in bioconjugation 
strategies; and in in vitro and in vivo imaging.69,75,76 The iedDA reaction of 1,2,4,5-
tetrazines has been considered to fulfil the criteria of a click reaction and therefore has 
found applications in material, polymer and supramolecular science.77-83 Further 
applications of the iedDA reaction of 1,2,4,5-tetrazines include targeted drug delivery, 
biomolecule immobilisation and natural product synthesis.84-86
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The aim of this thesis was to develop a novel solid-phase peptide macrocyclisation 
strategy based on the iedDA reaction of 1,2,4,5-tetrazines. A solid-phase peptide 
macrocyclisation strategy was selected due to their amenability to automated and 
combinatorial synthesis; and efficiency and simplicity over solution-phase 
strategies.87-89 Also, the pseudodilution effect can be exploited to favour 
intramolecular over intermolecular reactions in a solid-phase peptide macrocyclisation 
strategy.90-92 The iedDA reaction of 1,2,4,5-tetrazines was selected due to its 
efficiency, orthogonality, tunability and versatility as shown by its successful 
application in numerous fields of research.69,75,76,79-86 
 
It was initially proposed that 1,2,4,5-tetrazine and dienophile derivatised amino acids 
would be incorporated into propagating peptide chains to enable side chain-to-side 
chain and side chain-to-tail peptide macrocyclisations (Scheme 13A). However, due 
to the then unknown stability of 1,2,4,5-tetrazines towards the deprotection, coupling 
and cleavage cycles of solid-phase peptide synthesis (SPPS) it was decided to use an 
orthogonal deprotection strategy to enable late stage incorporation of the 1,2,4,5-
















Scheme 13A. 1,2,4,5-Tetrazine and dienophile derivatised amino acids incorporated into a 
propagating peptide chain to enable a side chain-to-side chain peptide macrocyclisation. Scheme 13B. 
Orthogonal deprotection strategy to enable late stage incorporation of the 1,2,4,5-tetrazine moiety 
onto the peptide backbone. 
 
A strategy was required to prevent any undesired iedDA reaction during the late stage 
incorporation of the 1,2,4,5-tetrazine moiety onto the peptide backbone in the presence 
of a dienophile (Scheme 14A). The solid-phase thermal activation peptide 
macrocyclisation strategy would use unreactive 1,2,4,5-tetrazine-dienophile pairs to 
enable late stage incorporation of the 1,2,4,5-tetrazine moiety onto the peptide 
backbone in the presence of a dienophile at rt (Scheme 14B). Conventional or 
microwave heating would then increase the rate of reaction to promote the iedDA 
reaction of the 1,2,4,5-tetrazine and therefore peptide macrocyclisation. However, the 
fine balance of reaction rates required for selective late stage incorporation of the 
1,2,4,5-tetrazine moiety onto the peptide backbone in the presence of a dienophile and 







Scheme 14A. Undesired iedDA reaction during the late stage incorporation of the 1,2,4,5-tetrazine 
moiety onto the peptide backbone in the presence of a dienophile. Scheme 14B. Solid-phase thermal 
activation peptide macrocyclisation strategy. 
 
An alternative strategy which would eliminate any competing iedDA reaction during 
the late stage incorporation of the 1,2,4,5-tetrazine moiety onto the peptide backbone 
in the presence of a dienophile was proposed. The solid-phase oxidation activation 
peptide macrocyclisation strategy would use the in situ oxidation of an unreactive 
dihydro-1,2,4,5-tetrazine to trigger the iedDA reaction and therefore peptide 
macrocyclisation (Scheme 15). The solid-phase oxidation activation peptide 
macrocyclisation strategy enables selective late stage incorporation of the dihydro-
1,2,4,5-tetrazine moiety onto the peptide backbone in the presence of a dienophile and 











Scheme 15. Solid-phase oxidation activation peptide macrocyclisation strategy. 
 
The solid-phase oxidation activation peptide macrocyclisation strategy was selected 
due to its advantages over the solid-phase thermal activation peptide macrocyclisation 
strategy. An additional advantage of the solid-phase oxidation activation peptide 
macrocyclisation strategy is that reactive 1,2,4,5-tetrazine-dienophile pairs can be used 
to enable fast rates of reaction. Also, oxidation of dihydropyridazine diastereomers 
with excess oxidant will give diastereomerically pure pyridazine and therefore 
diastereomerically pure macrocyclic peptides. However, to successfully develop a 
novel solid-phase peptide macrocyclisation strategy based on the in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine several prerequisites needed to be 
achieved. 
 
Firstly, a proof of concept in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-
tetrazine needed to be conducted to determine the viability of the solid-phase oxidation 
activation peptide macrocyclisation strategy. 
 
Secondly, optimisation of the proof of concept in situ oxidation and iedDA reaction of 
a dihydro-1,2,4,5-tetrazine would be required before transferring the optimised in situ 
oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine to solid-phase and 
verifying the in situ oxidation and iedDA reactions of resin-bound dihydro-1,2,4,5-




Finally, peptide macrocyclisations needed to be conducted to determine the scope and 
limitations of the solid-phase oxidation activation peptide macrocyclisation strategy.
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The aim of this chapter was to determine the viability of the solid-phase oxidation 
activation peptide macrocyclisation strategy by conducting a proof of concept in situ 
oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine (Scheme 16). However, 
to achieve a successful proof of concept in situ oxidation and iedDA reaction of a 




Scheme 16. In situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine. 
 
Firstly, a dihydro-1,2,4,5-tetrazine which can be readily oxidised to a reactive 1,2,4,5-
tetrazine with an oxidant which is amenable to SPPS needed to be identified and 
synthesised. Also, the dihydro-1,2,4,5-tetrazine required a functional handle to enable 
late stage incorporation of the dihydro-1,2,4,5-tetrazine moiety onto the peptide 
backbone. 
 
Secondly, a library of reactive dienophiles needed to be identified and synthesised to 
enable multiple 1,2,4,5-tetrazine-dienophile pairs to be screened. These dienophiles 
required a functional handle to enable amino acid derivatisation; and the resulting 
amino acids needed to be stable to the deprotection, coupling and cleavage cycles of 
SPPS. 
 
Finally, the iedDA reactions of the 1,2,4,5-tetrazine-dienophile pairs needed to be 





3.2. Selection and Synthesis of Dihydro-1,2,4,5-tetrazine 
 
Diester dihydrotetrazine 45 was selected for the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine as its synthesis had been previously 
reported within the literature;22 it can be readily oxidised to the reactive diester 
tetrazine 46 with an oxidant which is amenable to SPPS;80 and it contains two 
functional handles for the late stage incorporation of diester dihydrotetrazine 45 onto 
the peptide backbone and further derivatisation.20 
 
The established synthesis of diester dihydrotetrazine 45 was developed to enable a 
large-scale and reproducible synthesis of diester tetrazine 46.22 The dimerisation of 
diazo ester 47 in the presence of sodium hydroxide and subsequent protonation of the 
resulting sodium salt to give dicarboxylic acid dihydrotetrazine 48 was reported at 69-
76 % yield. Successive esterification of dicarboxylic acid dihydrotetrazine 48 with 
methanol in the presence of thionyl chloride to give diester dihydrotetrazine 45 was 
reported at 56-61 % yield. However, upon following the literature procedure diester 
dihydrotetrazine 45 was isolated in 15 % overall yield (Scheme 17). No optimisation 
was conducted to the literature procedure as sufficient material was obtained for the 
synthesis of diester tetrazine 46 and the proof of concept in situ oxidation and iedDA 




Scheme 17. Synthesis of diester tetrazine 46. Reagents and reaction conditions a) i) NaOH (4.6 eq), 
H2O, 70 °C, 1.5 h; ii) HCl, H2O, -10 °C;22 b) SOCl2 (2.6 eq), MeOH, 40 °C, 2 h, N2;22 c) isopentyl 




The oxidation of diester dihydrotetrazine 45 to give diester tetrazine 46 was reported 
at quantitative yield.22 However, the oxidation of diester dihydrotetrazine 45 was 
achieved with highly toxic nitrous gasses, generated in a separate reaction vessel by 
the disproportionation of nitrous acid, which are not amenable to SPPS. An alternative 
oxidation procedure which is amenable to SPPS used isopentyl nitrite to oxidise diester 
dihydrotetrazine 45 but was reported in the literature without a yield.80 Upon following 
the literature procedure diester tetrazine 46 was isolated in 48 % yield (Scheme 17). 
However, evidence of quantitative oxidation of diester dihydrotetrazine 45 with 
isopentyl nitrite was obtained by proton nuclear magnetic resonance (NMR) as no 
starting material, decomposition or side products were observed in the crude material. 
Therefore, it was concluded that isopentyl nitrite was a suitable oxidant for the proof 
of concept in situ oxidation and iedDA reaction a dihydro-1,2,4,5-tetrazine. However, 
a significant loss of diester tetrazine 46 occurs during recrystallisation. 
 
The (bis)transesterification of diester dihydrotetrazine 45 with primary alcohols in the 
presence of aluminium ethoxide to give symmetrical diester dihydro-1,2,4,5-tetrazines 
has been reported at 39-85 % yield;94 or with primary or secondary alcohols to obtain 
symmetrical and unsymmetrical diester dihydro-1,2,4,5-tetrazines at 21-44 % yield.20 
However, transesterification is not suitable for the late stage incorporation of diester 
dihydrotetrazine 45 onto the peptide backbone due to mechanistic considerations. The 
methanol generated in situ would need to be removed and/or a large excess of the 
corresponding alcohol would be required to push the equilibrium in favour of 
transesterification. Although both tactics were used for the bistransesterification of 
diester dihydrotetrazine 45 in the presence of aluminium ethoxide a near quantitative 
or quantitative yield was never reported in the literature. 
 
The bisamidation of diester dihydrotetrazine 45 with primary or secondary amines to 
give symmetrical diamide dihydro-1,2,4,5-tetrazines has been reported at 79-98 % 
yield.20 The near quantitative yields and absence of any mechanistic considerations 
make amidation with primary or secondary amines suitable for the late stage 
incorporation of diester dihydrotetrazine 45 onto the peptide backbone. Only a slight 
excess of the corresponding amine was reported in the literature for the bisamidation 
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of diester dihydrotetrazine 45 due to the increased nucleophilicity and decreased 
leaving group ability of amines relative to alcohols. However, a large excess of diester 
dihydrotetrazine 45 could be used to push the late stage incorporation of diester 
dihydrotetrazine 45 onto the peptide backbone if required. Therefore, the amidation of 
diester dihydrotetrazine 45 with primary or secondary amines was selected for the late 
stage incorporation of diester dihydrotetrazine 45 onto the peptide backbone. 
 
3.3. Selection and Synthesis of Dienophiles 
 
Strained cycloalkenes and cycloalkynes are highly reactive dienophiles in the iedDA 
reaction of 1,2,4,5-tetrazines as ring strain decreases the distortion energy required to 
reach the [4+2] cycloaddition transition state.95-97 Also, numerous strained 
cycloalkenes and cycloalkynes which contain functional handles are readily available 
due to their extensive use in strain-promoted bioconjugation strategies.69,75,98-100 
Furthermore, these dienophiles are readily incorporated into Nα-protected lysine and 
are stable to the deprotection, coupling and cleavage cycles of SPPS.101-103 Therefore, 
(E)-cycloalkene 49, cycloalkyne 50 and (Z)-bicycloalkene 51 were selected as model 




Figure 4. Dienophile selection for the iedDA reactions of diester tetrazine 46. 
 
Many syntheses of (E)-cycloalkene 49 have been reported within the literature.104-107 
However, it was decided to follow a literature procedure which used phosphine oxides 
to facilitate the isomerisation of (Z)-alkenes as it was the most established non-
photochemical synthesis of (E)-cycloalkene 49 within the literature.108,109 The 
epoxidation of (Z)-cycloalkene 52 with 3-chloroperbenzoic acid (mCPBA) to give 
cycloalkane epoxide 53 was reported at 98 % yield. Successive ring opening of 
cycloalkane epoxide 53 by the nucleophilic addition of lithiodiphenylphosphane; and 
subsequent oxidation and protonation of the resulting lithium salt to give (±)-trans-
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alcohol phosphine oxide cycloalkane 54 was reported at 77 % yield. The stereospecific 
base promoted elimination of sodium diphenylphosphinate from (±)-trans-alcohol 
phosphine oxide cycloalkane 54 to give (E)-cycloalkene 49 was reported at 58 % yield 
with less than 1 % (Z)-cycloalkene 52 impurity as determined by gas chromatography. 
Upon following the literature procedure (E)-cycloalkene 49 was isolated in 18 % 





Scheme 18. Synthesis of (E)-cycloalkene 49. Reagents and reaction conditions a) mCPBA (1 eq), 
DCM, rt, 5 h;108 b) i) LiPPh2 in THF (1.1 eq), THF, rt, 2 d, N2; ii) AcOH (1.25 eq), H2O2 in H2O, rt, 1 
h;108 c) NaH (1.2 eq), DMF, rt, 3 h, N2.108 
 
The established synthesis of cycloalkyne 50 was developed due to the inefficiencies 
of previous syntheses reported within the literature.110-112 The electrophilic addition of 
bromine to (Z)-cycloalkene 52 and subsequent dehydrobromination of (±)-trans-
dibromocycloalkane 55 with potassium tert-butoxide to give (E)-bromocycloalkene 
56 was reported at 72 % yield (over two steps). Successive dehydrobromination of (E)-
bromocycloalkene 56 with lithium diisopropylamide (LDA) to give cycloalkyne 50 
was reported at 80-84 % yield. However, upon following the literature procedure 
cycloalkyne 50 was isolated in 6 % overall yield (Scheme 19). A significant loss of 
material occurred during the distillation of cycloalkyne 50 due to the small scale of the 








Scheme 19. Synthesis of cycloalkyne 50. Reagents and reaction conditions a) Br2 (1 eq), DCM, -40 
°C, 30 min;110 b) tBuOK in THF (1.5 eq), Et2O, rt, 1 h, N2;110 c) LDA in hexanes and THF (0.5 eq), rt, 
2.5 h, N2.110 
 
No synthesis was required for (Z)-bicycloalkene 51 as it was commercially available. 
 
3.4. Inverse Electron Demand Diels-Alder Reactions 
 
The first iedDA reaction to be screened was the iedDA reaction of diester tetrazine 46 
with (Z)-bicycloalkene 51 as the synthesis of diester tricyclodihydropyridazine 57 had 
been previously reported within the literature.113 The iedDA reaction of diester 
tetrazine 46 with (Z)-bicycloalkene 51 to give diester tricyclodihydropyridazine 57 
was reported at 87 % yield in diethyl ether. Once the literature procedure had been 
verified the iedDA reaction of diester tetrazine 46 with (Z)-bicycloalkene 51 was 
repeated in dichloromethane (DCM) to give diester tricyclodihydropyridazine 57 in 79 
% isolated yield (Scheme 20). Also, the concentration of diester tetrazine 46 had been 
decreased from 0.2 to 0.1 moldm-3 (M). Although the iedDA reaction with (Z)-
bicycloalkene 51 had been left for 2 hours (h) it had gone to completion within a few 




Scheme 20. iedDA reaction of diester tetrazine 46 with (Z)-bicycloalkene 51. Reagents and reaction 




Alternative reaction conditions were used from those reported in the literature to mimic 
conditions commonly used in SPPS and therefore to be used for peptide 
macrocyclisation.113 Although N,N-dimethylformamide (DMF) is a more widely used 
solvent in SPPS it was not selected for the solid-phase oxidation activation peptide 
macrocyclisation strategy due to its residual water content and the poor hydrolytic 
stability of diester tetrazine 46.114 During a qualitative hydrolytic stability study of a 
library of 1,2,4,5-tetrazines complete hydrolysis of diester tetrazine 46 was observed 
after 30 minutes (min) in DMF (Figure 5). However, complete hydrolysis of diester 
tetrazine 46 was not observed even after 2 days (d) in the analogous qualitative 




Figure 5. Qualitative hydrolytic stability study of 0.1 M diester tetrazine 46. Complete hydrolysis of 
diester tetrazine 46 was indicated by a colour change from red to yellow. 
 
The second iedDA reaction to be screened was the iedDA reaction of diester tetrazine 
46 with (E)-cycloalkene 49 to give diester bicyclodihydropyridazine 58 (Scheme 21). 
With the alternative reaction conditions diester bicyclodihydropyridazine 58 was 
isolated in 74 % yield which was comparable to the yield achieved for the analogous 
(Z)-bicycloalkene 51 iedDA reaction. As expected, due to the increased reactivity of 
(E)-cycloalkene 49 over (Z)-bicycloalkene 51 in the iedDA reaction of 1,2,4,5-
tetrazines, the iedDA reaction with (E)-cycloalkene 49 had gone to completion within 






Scheme 21. iedDA reaction of diester tetrazine 46 with (E)-cycloalkene 49. Reagents and reaction 
conditions a) (E)-cycloalkene 49 (1.05 eq), DCM, rt, 2 h. 
 
The final iedDA reaction to be screened was the iedDA reaction of diester tetrazine 46 
with cycloalkyne 50 to give diester bicyclopyridazine 59 (Scheme 22). With the 
alternative reaction conditions diester bicyclopyridazine 59 was isolated in 92 % yield 
which was a significant improvement over the analogous (Z)-bicycloalkene 51 and 
(E)-cycloalkene 49 iedDA reactions. Again, although the iedDA reaction with 
cycloalkyne 50 had been left for 2 h it had gone to completion within a few minutes 




Scheme 22. iedDA reaction of diester tetrazine 46 with cycloalkyne 50. Reagents and reaction 
conditions a) cycloalkyne 50 (1.05 eq), DCM, rt, 2 h. 
 
Cycloalkyne 50 was selected as the model dienophile for the proof of concept in situ 
oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine due to its improved 
isolated yield over the analogous iedDA reactions of diester tetrazine 46 with (Z)-
bicycloalkene 51 and (E)-cycloalkene 49. Also, evidence of quantitative conversion to 
diester bicyclopyridazine 59 was obtained by proton NMR as no starting material, 
decomposition or side products were observed in the crude material. Furthermore, the 
direct formation of a diastereomerically pure pyridazine, when using an alkyne over 
an alkene dienophile, eliminates the oxidation of dihydropyridazine diastereomers and 
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therefore an additional level of complexity in the solid-phase oxidation activation 
peptide macrocyclisation strategy. 
 
3.5. In situ Oxidation and Inverse Electron Demand Diels-Alder Reactions 
 
As the oxidation of diester dihydrotetrazine 45 with isopentyl nitrite and the iedDA 
reaction of diester tetrazine 46 with cycloalkyne 50 were quantitative by proton NMR 
the in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with 
cycloalkyne 50 in the presence of isopentyl nitrite was optimised using proton NMR 
(Table 1). Initially 3 equivalents (eq) of isopentyl nitrite were used in the in situ 
oxidation and iedDA reaction of diester dihydrotetrazine 45 with cycloalkyne 50 to 
replicate the literature procedure for the oxidation of diester dihydrotetrazine 45 with 
isopentyl nitrite (Entry I).80 Quantitative oxidation to diester tetrazine 46 was achieved 
but the subsequent iedDA reaction with cycloalkyne 50 to give diester 
bicyclopyridazine 59 occurred in 60 % proton NMR yield. Decomposition of 
cycloalkyne 50 by isopentyl nitrite was proposed to provide a competing pathway 
which limited the iedDA reaction of diester tetrazine 46. The decomposition of 
cycloalkyne 50 by isopentyl nitrite was corroborated by conducting a stability study 
of cycloalkyne 50 towards isopentyl nitrite. Therefore, a second reaction was 
conducted with 1.05 eq of isopentyl nitrite to limit the decomposition of cycloalkyne 
50 but with an insignificant effect on the yields of diester tetrazine 46 and diester 
bicyclopyridazine 59 (Entry II). However, when a third iedDA reaction of diester 
dihydrotetrazine 45 with cycloalkyne 50 was conducted with 10 eq of isopentyl nitrite 
there was a significant improvement in the yield achieved for diester bicyclopyridazine 
59 (Entry III). When a final reaction was conducted with 25 eq of isopentyl nitrite the 
in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with cycloalkyne 
50 to give diester bicyclopyridazine 59 was achieved in quantitative proton NMR yield 
(Entry IV). The oxidation of diester dihydrotetrazine 45 with isopentyl nitrite was 
proposed to have a higher rate constant than the degradation of cycloalkyne 50 by 
isopentyl nitrite but not corroborated by conducting kinetic studies of the oxidation of 
diester dihydrotetrazine 45 with isopentyl nitrite or the degradation of cycloalkyne 50 
by isopentyl nitrite. Therefore, it was proposed that the in situ oxidation and iedDA of 
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diester dihydrotetrazine 45 with cycloalkyne 50 was favoured over the degradation of 
cycloalkyne 50 by isopentyl nitrite at increased concentrations of isopentyl nitrite. 
 
 
Entry Equivalents of 
Isopentyl Nitrite 
1H NMR Yield/%a,b 
46 59 
I 3 40 60 
II 1.05 43 57 
III 10 20 80 
IV 25 0 Quantitative 
 
Table 1. Optimisation of the in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with 
cycloalkyne 50 in the presence of isopentyl nitrite. Reagents and reaction conditions a) cycloalkyne 50 
(1.05 eq), isopentyl nitrite, DCM, rt, 2 h. a Pseudoquantitative 1H NMR yields were calculated from 
the ratio of diester tetrazine 46 to diester bicyclopyridazine 59 in the 1H NMR spectrum. b Diester 




The aim of this chapter was to determine the viability of the solid-phase oxidation 
activation peptide macrocyclisation strategy by conducting a proof of concept in situ 
oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine. 
 
Diester dihydrotetrazine 45 was selected for the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine as its synthesis had been previously 
reported within the literature;22 it can be readily oxidised to the reactive diester 
tetrazine 46 with isopentyl nitrite which is amenable to SPPS;80 and the amidation of 
diester dihydrotetrazine 45 with primary or secondary amines can be used for the late 




(E)-Cycloalkene 49, cycloalkyne 50 and (Z)-bicycloalkene 51 were selected as model 
dienophiles for the iedDA reactions of diester tetrazine 46 as strained cycloalkenes and 
cycloalkynes are highly reactive dienophiles in the iedDA reaction of 1,2,4,5-
tetrazines;95,96 numerous strained cycloalkenes and cycloalkynes which contain 
functional handles are available due to their extensive use in strain-promoted 
bioconjugation strategies;69,75,98-100 and these dienophiles are readily incorporated into 
Nα-protected lysine and are stable to the deprotection, coupling and cleavage cycles of 
SPPS.101-103 
 
Cycloalkyne 50 was selected as the model dienophile for the proof of concept in situ 
oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine due to its improved 
isolated yield over the analogous iedDA reactions of diester tetrazine 46 with (Z)-
bicycloalkene 51 and (E)-cycloalkene 49. 
 
The in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with 
cycloalkyne 50 in the presence of isopentyl nitrite to give diester bicyclopyridazine 59 
was achieved in quantitative proton NMR yield (Scheme 23). Therefore, a successful 
proof of concept in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine 
was achieved. However, the in situ oxidation and iedDA reaction of diester 
dihydrotetrazine 45 with cycloalkyne 50 in the presence of isopentyl nitrite also 




Scheme 23. In situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with cycloalkyne 50 
in the presence of isopentyl nitrite. Reagents and reaction conditions a) cycloalkyne 50 (1.05 eq), 
isopentyl nitrite (25 eq), DCM, rt, 2 h.
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The aim of this chapter was to optimise the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine so that the optimised in situ oxidation 
and iedDA reaction of diester dihydrotetrazine 45 can be transferred to solid-phase. 
Two strategies were proposed to overcome the poor stability of a strained dienophile 
towards an oxidant and therefore optimise the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine. 
 
Firstly, an alternative oxidant which does not facilitate decomposition of a strained 
dienophile can overcome the poor stability of a strained dienophile towards an oxidant. 
Therefore, a library of oxidants which are amenable to SPPS needed to be identified 
and their oxidation of diester dihydrotetrazine 45 screened before their use in an in situ 
oxidation and iedDA reaction of diester dihydrotetrazine 45. 
 
Secondly, an unstrained dienophile which is stable to decomposition by an oxidant can 
overcome the poor stability of a strained dienophile towards an oxidant. Therefore, a 
library of reactive unstrained dienophiles needed to be identified and synthesised. 
These dienophiles required a functional handle to enable amino acid derivatisation; 
and the resulting amino acids needed to be stable to the deprotection, coupling and 
cleavage cycles of SPPS. 
 
The iedDA reactions of diester tetrazine 46 with the unstrained dienophiles needed to 
be screened before their use in an in situ oxidation and iedDA reaction of diester 
dihydrotetrazine 45. 
 
4.2. Oxidation of Dihydro-1,2,4,5-tetrazine 
 
A quantitative analytic technique was required to enable an efficient and high-
throughput investigation into the oxidation of diester dihydrotetrazine 45 which 
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negated the requirement to isolate diester tetrazine 46. Quantitative nuclear magnetic 
resonance (qNMR) spectroscopy was selected for the investigation into the oxidation 
of diester dihydrotetrazine 45 as it fulfilled the requirements of the investigation but 
could also be used to monitor iedDA reactions of diester tetrazine 46 and investigate 
in situ oxidation and iedDA reactions of diester dihydrotetrazine 45. 1,2,4,5-
Tetramethylbenzene (durene) was selected as the qNMR internal standard as it was 
commercially available as a qNMR internal standard; and its ArH and ArCH3 peaks 
would not overlap with additional peaks in the proton NMR spectra and therefore 
prevent accurate calculation of qNMR yields. No optimisation was required to the 
open access proton NMR experimental parameters for qNMR as verified by 
authenticated samples of diester dihydrotetrazine 45 and diester tetrazine 46 in the 
presence of durene. 
 
Oxidants were selected for the investigation into the oxidation of diester 
dihydrotetrazine 45 which are amenable to SPPS and had been previously reported 
within the literature for the oxidation of a dihydro-1,2,4,5-tetrazine or a 
dihydropyridazine (Table 2).115-122 During the investigation into the oxidation of 
diester dihydrotetrazine 45 3 eq of oxidant were used to replicate the literature 
procedure for the oxidation of diester dihydrotetrazine 45 with isopentyl nitrite.80 
Unexpectedly, the oxidation of diester dihydrotetrazine 45 with isopentyl nitrite to give 
diester tetrazine 46 was achieved in 65 % qNMR yield (Entry I). However, no starting 
material, decomposition or side products were observed in the proton NMR spectrum. 
Intermolecular proton spin energy transfer between diester tetrazine 46 and isopentyl 
nitrite was proposed but discredited by an authenticated sample of diester tetrazine 46 
and isopentyl nitrite in the presence of durene. The analogous 2,3-dichloro-5,6-
dicyano-p-benzoquinone (DDQ), [bis(trifluoroacetoxy)iodo]benzene (BTI) and 4-
phenyl-1,2,4-triazoline-3,5-dione (PTAD) oxidations were achieved in quantitative 
qNMR yield whilst partial oxidation was achieved in the diethyl azodicarboxylate 
(DEAD) and chloranil reactions (Entries II-IV and VI-VII). The qNMR results of the 
oxidation of diester dihydrotetrazine 45 with DDQ, BTI and PTAD were corroborated 
by authenticated samples of diester tetrazine 46 and the respective oxidant in the 
presence of durene. The oxidation of diester dihydrotetrazine 45 with ammonium 
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cerium(IV) nitrate (CAN) and trimethylphenylammonium tribromide (TPAT) to give 
diester tetrazine 46 was observed in 88 and 7 % qNMR yield respectively (Entries V 
and VIII). Decomposition of diester tetrazine 46 by CAN and TPAT was proposed but 




Entry Oxidant qNMR Yield/% 
45 46 
I Isopentyl nitrite 0 65 
II DDQ 0 Quantitative 
III DEAD 89 11 
IV BTI 0 Quantitative 
V CAN 0 88 
VI Chloranil 94 6 
VII PTAD 0 Quantitative 
VIII TPAT 75 7 
 
Table 2. Investigation into the oxidation of diester dihydrotetrazine 45. Reagents and reaction 
conditions a) durene (0.5 eq), oxidant (3 eq), DCM-d2, 25 °C, 2 h. 
 
DDQ, BTI and PTAD were selected as alternative oxidants to optimise the proof of 
concept in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine due to their 
corroborated quantitative qNMR yields in the oxidation of diester dihydrotetrazine 45. 
 
4.3. Selection and Synthesis of Dienophiles 
 
endo- and exo-BCN-OH 60 were selected as dienophiles for the iedDA reactions of 
diester tetrazine 46 as they are highly reactive in the iedDA reaction of 1,2,4,5-
tetrazines; are readily incorporated into Fmoc-Lys-OH hydrochloride; and are stable 
to the deprotection, coupling and cleavage cycles of SPPS (Figure 6).100,103,123 Also, 
the iedDA reaction of diester tetrazine 46 with endo- and exo-BCN-OH 60 will give a 
single regioisomerically pure pyridazine due to the Cs symmetry of endo- and exo-
BCN-OH 60. Unstrained cycloalkenes and terminal alkenes are reactive dienophiles 
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in the iedDA reaction of 1,2,4,5-tetrazines.95,96 Therefore, (±)-(Z)-cycloalkene alcohol 
61, allyl amide 62 and allyl ester 63 were selected as dienophiles for the iedDA 
reactions of diester tetrazine 46. (±)-(Z)-cycloalkene alcohol 61 contains a functional 
handle for amino acid derivatisation whilst allyl amide 62 and allyl ester 63 model 
Nβ/γ-allyl amine derivatised Fmoc-Asp-OH and Fmoc-Glu-OH; and Fmoc-Asp(OAll)-




Figure 6. Dienophile selection for the iedDA reactions of diester tetrazine 46. 
 
The established synthesis of endo- and exo-BCN-OH 60 was developed to provide a 
highly reactive, novel and readily accessible strained cycloalkyne for use in strain-
promoted bioconjugation strategies.100 The cyclopropanation of cyclodiene 64 with 
ethyl diazoacetate in the presence of rhodium(II) acetate dimer to give (Z)-endo- and 
(Z)-exo-bicycloalkene ester 65 was reported at 25 and 51 % yield respectively after 
diasteromeric separation by flash column chromatography. Successive reduction of 
(Z)-endo-bicycloalkene ester 65 with lithium aluminium hydride was reported to give 
(Z)-endo-bicycloalkene alcohol 66. The electrophilic addition of bromine to (Z)-endo-
bicycloalkene alcohol 66 and subsequent bisdehydrobromination of (±)-endo,trans-
dibromobicycloalkane alcohol 67 with potassium tert-butoxide to give endo-BCN-OH 
60 was reported at 61 % yield (over three steps). The analogous reduction, electrophilic 
addition and bisdehydrobromination of (Z)-exo-bicycloalkene ester 65 to give exo-
BCN-OH 60 was reported at 53 % yield. Upon following the literature procedure with 
additional purifications endo- and exo-BCN-OH 60 were isolated in 8 and 11 % overall 






Scheme 24. Syntheses of endo- and exo-BCN-OH 60. Reagents and reaction conditions a) Rh2(OAc)4 
(5 mol%), ethyl diazoacetate (0.125 eq), DCM, rt, 40 h, N2;100 b) LiAlH4 (0.9 eq), Et2O, rt, 30 min, 
N2;100 c) Br2 (1.1 eq), DCM, 0 °C, 30 min;100 d) tBuOK in THF(3.3 eq), THF, reflux, 2 h, N2.100 
 
The established synthesis of (±)-(Z)-cycloalkene alcohol 61 was developed to enable 
the synthesis of 9-oxabicyclo[6.1.0]non-3-yne.124,125 The epoxidation of cyclodiene 64 
with mCPBA to give (Z)-cycloalkene epoxide 68 was reported at 66 % yield. 
Successive ring opening of (Z)-cycloalkene epoxide 68 by the nucleophilic addition of 
lithium aluminium hydride and subsequent protonation of the resulting lithium salt to 
give (±)-(Z)-cycloalkene alcohol 61 was reported at quantitative yield. However, upon 
following the literature procedure (±)-(Z)-cycloalkene alcohol 61 was isolated in 40 % 
overall yield (Scheme 25). No optimisation was conducted to the literature procedure 




Scheme 25. Synthesis of (±)-(Z)-cycloalkene alcohol 61. Reagents and reaction conditions a) mCPBA 
(1 eq), CHCl3, rt, ~18 h;125 b) LiAlH4 in THF (0.5 eq), THF, rt, ~18 h, N2.125 
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The nucleophilic substitution of propionyl chloride with allyl amine 69 in the presence 





Scheme 26. Synthesis of allyl amide 62. Reagents and reaction conditions a) EtCOCl (1 eq), Et3N (1.2 
eq), DCM, rt, 2 h. 
 
No synthesis was required for allyl ester 63 as it was commercially available. 
 
4.4. Inverse Electron Demand Diels-Alder Reactions 
 
The first iedDA reactions to be screened were the iedDA reactions of diester tetrazine 
46 with endo- and exo-BCN-OH 60 (Scheme 27). The iedDA reactions of diester 
tetrazine 46 with endo- and exo-BCN-OH 60 to give endo- and exo-diester 
tricyclopyridazine alcohol 70 were achieved in quantitative qNMR yield. As expected, 
no observable differences were encountered between the iedDA reactions of diester 
tetrazine 46 with endo- and exo-BCN-OH 60.100 Although the iedDA reactions with 
endo- and exo-BCN-OH 60 had been left for 2 h they had gone to completion within a 
few minutes as indicated by the loss of red colour from diester tetrazine 46. To 
corroborate the qNMR results endo- and exo-diester tricyclopyridazine alcohol 70 







Scheme 27. iedDA reactions of diester tetrazine 46 with endo- and exo-BCN-OH 60. Reagents and 
reaction conditions a) durene (0.5 eq), endo- or exo-BCN-OH 60 (1.05 eq), DCM-d2, 25 °C, 2 h. a 
endo-diester tricyclopyridazine alcohol 70 was isolated in 85 % yield. b exo-diester tricyclopyridazine 
alcohol 70 was isolated in 89 %. 
 
The second iedDA reaction to be screened was the iedDA reaction of diester tetrazine 
46 with (±)-(Z)-cycloalkene alcohol 61 (Scheme 28). The iedDA reaction of diester 
tetrazine 46 with (±)-(Z)-cycloalkene alcohol 61 to give (±)-diester 
bicyclodihydropyridazine alcohol 71 as a mixture of two tautomers was achieved in 
79 % qNMR yield. The major tautomer was identified by characteristic RNHN and 
R3CH peaks in the proton NMR spectrum. However, several diastereomers and 
regioisomers of the major tautomer exist which are not distinguishable by one 
dimensional proton NMR. A minor tautomer was identified due to the presence of 
additional RNHN and CO2CH3 peaks in the proton NMR spectrum but could not be 
assigned without characteristic peaks. Although the iedDA reaction with (±)-(Z)-
cycloalkene alcohol 61 had been left for 2 h it had gone to completion within 1 h as 
indicated by the loss of red colour from diester tetrazine 46. No attempts were made 
to corroborate the qNMR result by isolating (±)-diester bicyclodihydropyridazine 
alcohol 71 due to the quantitative qNMR yield achieved in the analogous endo- and 






Scheme 28. iedDA reaction of diester tetrazine 46 with (±)-(Z)-cycloalkene alcohol 61. Reagents and 
reaction conditions a) durene (0.5 eq), (±)-(Z)-cycloalkene alcohol 61 (1.05 eq), DCM-d2, 25 °C, 2 h. a 
Not corroborated by the isolation of (±)-diester bicyclodihydropyridazine alcohol 71. 
 
The third iedDA reaction to be screened was the iedDA reaction of diester tetrazine 46 
with allyl amide 62 (Scheme 29). The iedDA reaction of diester tetrazine 46 with allyl 
amide 62 to give diester dihydropyridazine amide 72 as a mixture of three tautomers 
was achieved in 94 % qNMR yield. The major tautomer was assigned by characteristic 
RNHN, RCHR and R3CH peaks in the proton NMR spectrum. Two minor tautomers 
were identified due to the presence of additional CO2CH3, NHCOCH2R and RCH3 
peaks in the proton NMR spectrum but could not be assigned without characteristic 
peaks. Although the iedDA reaction with allyl amide 60 had been left for 2 h it had 
gone to completion within 1.5 h as indicated by the loss of red colour from diester 
tetrazine 46. All attempts to isolate diester dihydropyridazine amide 72 were 
unsuccessful and therefore the qNMR result was not corroborated by the isolation of 






Scheme 29. iedDA reaction of diester tetrazine 46 with allyl amide 62. Reagents and reaction 
conditions a) durene (0.5 eq), allyl amide 62 (1.05 eq), DCM-d2, 25 °C, 2 h. a Not corroborated by the 
isolation of diester dihydropyridazine amide 72. 
 
The final iedDA reaction to be screened was the iedDA reaction of diester tetrazine 46 
with allyl ester 63 (Scheme 30). The iedDA reaction of diester tetrazine 46 with allyl 
ester 63 to give diester dihydropyridazine ester 73 as a mixture of two tautomers was 
achieved in 96 % qNMR yield. The major tautomer was assigned by characteristic 
RNHN, RCHR and R3CH peaks in the proton NMR spectrum. A minor tautomer was 
identified due to the presence of additional CO2CH3, OCOCH2R and RCH3 peaks in 
the proton NMR spectrum but could not be assigned without characteristic peaks. As 
expected, due to the increased electronegativity of oxygen over nitrogen and the 
inductive effect, the iedDA reaction of diester tetrazine 46 with allyl ester 63 exhibited 
a slower rate of reaction than the analogous allyl amide 62 iedDA reaction. To 







Scheme 30. iedDA reaction of diester tetrazine 46 with allyl ester 63. Reagents and reaction 
conditions a) durene (0.5 eq), allyl ester 63 (1.05 eq), DCM-d2, 25 °C, 2 h. a Diester dihydropyridazine 
ester 73 was isolated in 84 %. 
 
endo-BCN-OH 60 and allyl ester 63 were selected as dienophiles to optimise the proof 
of concept in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine due to 
their corroborated quantitative and near quantitative qNMR yield respectively in the 
iedDA reactions of diester tetrazine 46. endo-BCN-OH 60 was selected as a dienophile 
to optimise the proof of concept in situ oxidation and iedDA reaction of a dihydro-
1,2,4,5-tetrazine over exo-BCN-OH 60 as this diastereomer was commercially 
available. Although a near quantitative qNMR yield had been achieved for the iedDA 
reaction of diester tetrazine 46 with allyl amide 62 this result was not corroborated by 
the isolation of diester dihydropyridazine amide 72. Therefore, allyl amide 62 was not 
selected as a dienophile to optimise the proof of concept in situ oxidation and iedDA 






4.5. In situ Oxidation and Inverse Electron Demand Diels-Alder Reactions 
 
The first in situ oxidation and iedDA reaction to be investigated was the in situ 
oxidation and iedDA reaction of diester dihydrotetrazine 45 with endo-BCN-OH 60 
(Table 3). The in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with 
endo-BCN-OH 60 in the presence of DDQ to give endo-diester tricyclopyridazine 
alcohol 70 was achieved in 97 % qNMR yield (Entry I). However, diester 
dihydrotetrazine 45, diester tetrazine 46 and endo-diester tricyclopyridazine alcohol 
70 were not observed by proton NMR in the analogous BTI in situ oxidation and 
iedDA reaction (Entry II). Decomposition of endo-diester tricyclopyridazine alcohol 
70 by BTI was proposed but not corroborated by conducting a stability study of endo-
diester tricyclopyridazine alcohol 70 towards BTI. In the presence of PTAD 
quantitative oxidation to diester tetrazine 46 was observed but the subsequent iedDA 
reaction with endo-BCN-OH 60 occurred in 61 % qNMR yield (Entry III). 
Decomposition of endo-BCN-OH 60 by PTAD provided a competing pathway which 
limited the iedDA reaction of diester tetrazine 46 with endo-BCN-OH 60. No 
optimisation was conducted to the in situ oxidation and iedDA reaction of diester 
dihydrotetrazine 45 with endo-BCN-OH 60 in the presence of PTAD due to the near 












Entry Oxidant qNMR Yield/%a
 
46 70 
I DDQ 0 97 
II BTI 0 0 
IIIb PTAD 38 61 
 
Table 3. Investigation into the in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 
with endo-BCN-OH 60. Reagents and reaction conditions a) durene (0.5 eq), endo-BCN-OH 60 (1.05 
eq), oxidant (3 eq), DCM-d2, 25 °C, 2 h. a Diester dihydrotetrazine 45 was not observed. b endo-BCN-
OH 60 was not observed. 
 
The final in situ oxidation and iedDA reaction to be investigated was the in situ 
oxidation and iedDA reaction of diester dihydrotetrazine 45 with allyl ester 63 (Table 
4). The in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with allyl 
ester 63 in the presence of DDQ and subsequent oxidation of diester dihydropyridazine 
ester 73 to give diester pyridazine ester 74 was achieved in quantitative qNMR yield 
(Entry I). To corroborate the qNMR result diester pyridazine ester 74 was isolated in 
97 % yield. Diester dihydrotetrazine 45, diester tetrazine 46, diester dihydropyridazine 
ester 73 and diester pyridazine ester 74 were not observed by proton NMR in the 
analogous BTI in situ oxidation and iedDA reaction (Entry II). Decomposition of 
diester dihydropyridazine ester 73 and/or diester pyridazine ester 74 by BTI was 
proposed but not corroborated by conducting stability studies of diester 
dihydropyridazine ester 73 and diester pyridazine ester 74 towards BTI. The in situ 
oxidation and iedDA reaction of diester dihydrotetrazine 45 with ally ester 63 in the 
presence of PTAD to give diester pyridazine ester 74 occurred in 31 % qNMR yield 
(Entry III). However, diester dihydrotetrazine 45, diester tetrazine 46, and diester 
dihydropyridazine ester 73 were not observed by proton NMR. Therefore, 
decomposition of diester pyridazine ester 74 by PTAD was proposed but with a slower 
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rate of decomposition than the proposed decomposition of diester dihydropyridazine 
ester 73 and/or diester pyridazine ester 74 by BTI. 
 
 
Entry Oxidant qNMR Yield/%a 
74 
I DDQ Quantitativeb 
II BTI 0 
III PTAD 31 
 
Table 4. Investigation into the in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 
with allyl ester 63. Reagents and reaction conditions a) durene (0.5 eq), allyl ester 63 (1.05 eq), 
oxidant (3 eq), DCM-d2, 25 °C, 2 h. a Diester dihydrotetrazine 45, diester tetrazine 46 and diester 




The aim of this chapter was to optimise the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine so that the optimised in situ oxidation 
and iedDA reaction of diester dihydrotetrazine 45 can be transferred to solid-phase. 
Two strategies were proposed to overcome the poor stability of a strained dienophile 
towards an oxidant and therefore optimise the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine. 
 
Firstly, an alternative oxidant which does not facilitate decomposition of a strained 
dienophile can overcome the poor stability of a strained dienophile towards an oxidant. 
Oxidants were selected for the investigation into the oxidation of diester 
dihydrotetrazine 45 which are amenable to SPPS and had been previously reported 
within the literature for the oxidation of a dihydro-1,2,4,5-tetrazine or a 
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dihydropyridazine.115-122 DDQ, BTI and PTAD were selected as alternative oxidants 
to optimise the proof of concept in situ oxidation and iedDA reaction of a dihydro-
1,2,4,5-tetrazine due to their corroborated quantitative qNMR yields in the oxidation 
of diester dihydrotetrazine 45. 
 
Secondly, an unstrained dienophile which is stable to decomposition by an oxidant can 
overcome the poor stability of a strained dienophile towards an oxidant. (±)-(Z)-
cycloalkene alcohol 61, allyl amide 62 and allyl ester 63 were selected as dienophiles 
for the iedDA reaction of diester tetrazine 46 as unstrained cycloalkenes and terminal 
alkenes are reactive dienophiles in the iedDA reaction of 1,2,4,5-tetrazines.95,96 (±)-
(Z)-cycloalkene alcohol 61 contains a functional handle for amino acid derivatisation 
whilst allyl amide 62 and allyl ester 63 model Nβ/γ-allyl amine derivatised Fmoc-Asp-
OH and Fmoc-Glu-OH; and Fmoc-Asp(OAll)-OH and Fmoc-Glu(OAll)-OH 
respectively. 
 
endo-BCN-OH 60 and allyl ester 63 were selected as dienophiles to optimise the proof 
of concept in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine due to 
their corroborated quantitative and near quantitative qNMR yield respectively in the 
iedDA reactions of diester tetrazine 46. endo-BCN-OH 60 was selected as a dienophile 
to optimise the proof of concept in situ oxidation and iedDA reaction of a dihydro-
1,2,4,5-tetrazine over exo-BCN-OH 60 as this diastereomer was commercially 
available. 
 
The in situ oxidation and iedDA reactions of diester dihydrotetrazine 45 with endo-
BCN-OH 60 and allyl ester 63 in the presence of DDQ to give endo-diester 
tricyclopyridazine alcohol 70 and diester pyridazine ester 74 were achieved in 97 % 
and quantitative qNMR yield respectively (Scheme 31). Therefore, the proof of 
concept in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine was 
successfully optimised in the presence of an alternative oxidant and with an unstrained 






Scheme 31. In situ oxidation and iedDA reactions of diester dihydrotetrazine 45 with endo-BCN-OH 
60 and allyl ester 63 in the presence of DDQ. Reagents and reaction conditions a) durene (0.5 eq), 
endo-BCN-OH 60 or allyl ester 63 (1.05 eq), DDQ (3 eq), DCM-d2, 25 °C, 2 h. a Diester pyridazine 
ester 74 was isolated in 97 % yield.
45 
 




The aims of this chapter were to transfer the optimised in situ oxidation and iedDA 
reactions of diester dihydrotetrazine 45 to solid-phase and to verify the in situ 
oxidation and iedDA reactions of resin-bound diester dihydrotetrazine derivatised 
amino acids in the presence of DDQ so that peptide macrocyclisations can be 
conducted on solid-phase (Scheme 32A and 32B). However, to successfully transfer 
the optimised in situ oxidation and iedDA reactions of diester dihydrotetrazine 45 to 
solid-phase and to verify the in situ oxidation and iedDA reactions of resin-bound 
diester dihydrotetrazine derivatised amino acids in the presence of DDQ several 




Scheme 32A. In situ oxidation and iedDA reaction of diester dihydrotetrazine 45 transferred to solid-
phase. Scheme 32B. In situ oxidation and iedDA reaction of resin-bound diester dihydrotetrazine 
derivatised amino acid. 
 
Firstly, the stability of resin-bound amino acids towards DDQ needed to be determined 
before transferring the optimised in situ oxidation and iedDA reactions of diester 
dihydrotetrazine 45 to solid-phase and verifying the in situ oxidation and iedDA 
reactions of resin-bound diester dihydrotetrazine derivatised amino acids in the 




Secondly, Fmoc-Lys(endo-BCN)-OH 75 needed to be synthesised and the in situ 
oxidation and iedDA reactions of diester dihydrotetrazine 45 with resin-bound 
dienophiles in the presence of DDQ needed to be conducted to enable the optimised in 
situ oxidation and iedDA reactions of diester dihydrotetrazine 45 to be transferred to 
solid-phase. 
 
Thirdly, resin-bound diester dihydrotetrazine derivatised amino acids needed to be 
synthesised to verify the late stage incorporation of diester dihydrotetrazine 45 onto 
the peptide backbone and the in situ oxidation and iedDA reactions of resin-bound 
diester dihydrotetrazine derivatised amino acids in the presence of DDQ. 
 
Finally, the in situ oxidation and iedDA reactions of resin-bound diester 
dihydrotetrazine derivatised amino acids with endo-BCN-OH 60 and allyl ester 63 in 
the presence of DDQ needed to be conducted to verify the in situ oxidation and iedDA 
reactions of resin-bound diester dihydrotetrazine derivatised amino acids in the 
presence of DDQ. 
 
5.2. Stability of Resin-Bound Amino Acids towards Oxidant 
 
An analytical technique was required to enable an efficient and high-throughput 
investigation into the stability of resin-bound amino acids towards DDQ. Analytical 
high-performance liquid chromatography (HPLC) was selected in combination with 
low-resolution mass spectroscopy (LRMS) for the investigation into the stability of 
resin-bound amino acids towards DDQ as these are commonly used analytical 
techniques to characterise peptides. 
 
Commercially available Nα-9-fluorenylmethoxycarbonyl (Fmoc) protected standard 
proteinogenic amino acids were selected for the investigation into the stability of resin-
bound amino acids towards DDQ as these are commonly used amino acids in SPPS 
and therefore to be used for peptide macrocyclisation (Table 5). However, any standard 
proteinogenic amino acids without a reactive functional group in their side chain were 
not included in the investigation into the stability of resin-bound amino acids towards 
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DDQ. All the standard proteinogenic amino acids with a reactive functional group in 
their side chain were protected with trifluoroacetic acid (TFA)-labile protecting groups 
which are orthogonal to the Fmoc protecting group, except Fmoc-Met-OH, to enable 
global deprotection of the macrocyclic peptide during linker cleavage. Rink amide 
polystyrene resin 76 was selected for the investigation into the stability of resin-bound 
amino acids towards DDQ as this resin was commercially available at various loading 
values and could therefore be used for both linear and macrocyclic peptide synthesis. 
 
 
Entry Fmoc-Aaa-OH HPLCb 
79a Purity/% 
I Fmoc-Arg(Pbf)-OH Fmoc-Arg-NH2 100 
II Fmoc-Asn(Trt)-OH Fmoc-Asn-NH2 100 
III Fmoc-Asp(OtBu)-OH Fmoc-Asp-NH2 100 
IV Fmoc-Cys(Trt)-OH Fmoc-Cys-NH2 100 
V Fmoc-Gln(Trt)-OH Fmoc-Gln-NH2 100 
VI Fmoc-Glu(OtBu)-OH Fmoc-Glu-NH2 100 
VII Fmoc-His(Trt)-OH Fmoc-His-NH2 100 
VIII Fmoc-Lys(Boc)-OH Fmoc-Lys-NH2 100 
IX Fmoc-Met-OH Fmoc-Met-NH2 96 
X Fmoc-Ser(tBu)-OH Fmoc-Ser-NH2 100 
XI Fmoc-Thr(tBu)-OH Fmoc-Thr-NH2 100 
XII Fmoc-Trp(Boc)-OH Fmoc-Trp-NH2 100 
XIII Fmoc-Tyr(tBu)-OH Fmoc-Tyr-NH2 100 
 
Table 5. Investigation into the stability of resin-bound amino acids towards DDQ. Reagents and 
reaction conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; b) i) 
piperidine in DMF, rt, 5 min; ii) Fmoc-Aaa-OH (3eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; c) 
i) DDQ (3 eq), DCM, rt, 8 h; ii) TFA:TIS:DCM (90:5:5), rt, 1 h. a Identified by LRMS. b ELSD. 
 
The resin functionalisation of amino polystyrene resin 77 with 4-[(2,4-
dimethoxyphenyl)(Fmoc-amino)methyl]phenoxyacetic acid (Rink amide linker) in the 
presence of ethyl (hydroxyimino)cyanoacetate (oxyma) and N,N`-
diisopropylcarbodiimide (DIC) gave Rink amide polystyrene resin 76 (Table 5). 
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Successive Fmoc deprotection of Rink amide polystyrene resin 76 with piperidine and 
subsequent amino acid coupling of Fmoc-Aaa-OH in the presence of oxyma and DIC 
gave resin-bound Fmoc-Aaa-OH 78. Exposure of resin-bound Fmoc-Aaa-OH 78 to 
DDQ and subsequent linker cleavage with TFA:triisopropylsilane (TIS):DCM gave 
Fmoc-Aaa-NH2 79. During the investigation into the stability of resin-bound amino 
acids towards DDQ 3 eq of oxidant were used to mimic the reaction conditions to be 
used for peptide macrocyclisation. The resin-bound Fmoc-Aaa-OH 78 was exposed to 
DDQ for 8 h as the optimised in situ oxidation and iedDA reactions of diester 
dihydrotetrazine 45 had gone to completion within 2 h. Therefore, the stability of resin-
bound Fmoc-Aaa-OH 78 towards DDQ was tested beyond the exposure limits 
expected for peptide macrocyclisation. No decomposition, deprotection or oxidation 
of resin-bound Fmoc-Aaa-OH 78 by DDQ was observed by analytical HPLC for the 
standard proteinogenic amino acids with a protected reactive functional group in their 
side chain (Entries I-XIII and X-XIII). However, insignificant decomposition or 
oxidation of resin-bound Fmoc-Met-OH by DDQ was observed by analytical HPLC 
(Entry IX). 
 
5.3. Synthesis of Dienophile Derivatised Amino Acid 
 
The established synthesis of Fmoc-Lys(exo-BCN)-OH 75 was developed to enable the 
site-specific incorporation of H-Lys(exo-BCN)-OH into proteins expressed in 
Escherichia coli and mammalian cells.103 The activation of exo-BCN-OH 60 with 
N,N`-disuccinimidyl carbonate (DSC) in the presence of triethylamine was reported to 
give exo-BCN-OSu 80. Successive derivatisation of Fmoc-Lys-OH hydrochloride 
with exo-BCN-OSu 80 in the presence of N,N-diisopropylethylamine (DIPEA) to give 
Fmoc-Lys(exo-BCN)-OH 75 was reported at 85 % yield (over two steps). Upon 
following the literature procedure with endo-BCN-OH 60 and an additional 







Scheme 33. Synthesis of Fmoc-Lys(endo-BCN)-OH 75. Reagents and reaction conditions a) Et3N (4 
eq), DSC (1.5 eq), MeCN, rt, 4 h, N2;103 b) Fmoc-Lys-OH.HCl (1.5 eq), DIPEA (2 eq), DMF, rt, ~18 
h, N2.103 
 
No synthesis was required for Fmoc-Asp(OAll)-OH and Fmoc-Glu(OAll)-OH as they 
were commercially available. 
 
5.4. In situ Oxidation and Inverse Electron Demand Diels-Alder Reactions 
 
The first optimised in situ oxidation and iedDA reaction of diester dihydrotetrazine 45 
to be transferred to solid-phase was the in situ oxidation and iedDA reaction of diester 
dihydrotetrazine 45 with endo-BCN-OH 60 (Scheme 34). The resin functionalisation 
of amino polystyrene resin 77 with Rink amide linker in the presence of oxyma and 
DIC gave Rink amide polystyrene resin 76. Successive Fmoc deprotection of Rink 
amide polystyrene resin 76 with piperidine and subsequent amino acid coupling of 
Fmoc-Lys(endo-BCN)-OH 75 in the presence of oxyma and DIC gave resin-bound 
Fmoc-Lys(endo-BCN)-OH 81. The in situ oxidation and iedDA reaction of diester 
dihydrotetrazine 45 with resin-bound Fmoc-Lys(endo-BCN)-OH 81 in the presence of 
DDQ gave resin-bound endo-diester tricyclopyridazine derivatised Fmoc-Lys-OH. 
Successive linker cleavage of resin-bound endo-diester tricyclopyridazine derivatised 
Fmoc-Lys-OH with TFA:TIS:DCM to give endo-diester tricyclopyridazine 
derivatised Fmoc-Lys-NH2 82 was achieved in 84 % overall isolated yield. The in situ 
oxidation and iedDA reaction of diester dihydrotetrazine 45 with resin-bound Fmoc-
Lys(endo-BCN)-OH 81 had been left for 4 h as the reaction could not be readily 
monitored. However, it was confirmed that the in situ oxidation and iedDA reaction of 
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diester dihydrotetrazine 45 with resin-bound Fmoc-Lys(endo-BCN)-OH 81 had gone 
to completion as Fmoc-Lys(endo-BCN)-NH2 was not observed in the crude material 
by analytical HPLC or LRMS. Also, no evidence of ester hydrolysis of endo-diester 
tricyclopyridazine derivatised Fmoc-Lys-NH2 82 by TFA was observed in the crude 




Scheme 34. In situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with resin-bound 
Fmoc-Lys(endo-BCN)-OH 81 in the presence of DDQ. Reagents and reaction conditions a) Rink 
amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; b) i) piperidine in DMF, rt, 5 min; ii) 
Fmoc-Lys(endo-BCN)-OH 75 (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; c) i) diester 
dihydrotetrazine 45 (1.05 eq), DDQ (3 eq), DCM, rt, 4 h; ii) TFA:TIS:DCM (90:5:5), rt, 3 h. 
 
The final optimised in situ oxidation and iedDA reaction of diester dihydrotetrazine 
45 to be transferred to solid-phase was the in situ oxidation and iedDA reaction of 
diester dihydrotetrazine 45 with allyl ester 63 (Scheme 35). The resin functionalisation 
of amino polystyrene resin 77 with Rink amide linker in the presence of oxyma and 
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DIC gave Rink amide polystyrene resin 76. Successive Fmoc deprotection of Rink 
amide polystyrene resin 76 with piperidine and subsequent amino acid coupling of 
Fmoc-Asp(OAll)-OH in the presence of oxyma and DIC gave resin-bound Fmoc-
Asp(OAll)-OH 83. The in situ oxidation and iedDA reaction of diester 
dihydrotetrazine 45 with resin-bound Fmoc-Asp(OAll)-OH 83 in the presence of DDQ 
gave resin-bound diester pyridazine derivatised Fmoc-Asp-OH. Successive linker 
cleavage of resin-bound diester pyridazine derivatised Fmoc-Asp-OH with 
TFA:TIS:DCM to give diester pyridazine derivatised Fmoc-Asp-NH2 84 was achieved 
in 95 % overall isolated yield. The in situ oxidation and iedDA reaction of diester 
dihydrotetrazine 45 with resin-bound Fmoc-Asp(OAll)-OH 83 had been left for 4 h as 
the reaction could not be readily monitored. However, it was confirmed that the in situ 
oxidation and iedDA reaction of diester dihydrotetrazine 45 with resin-bound Fmoc-
Asp(OAll)-OH 83 had gone to completion as Fmoc-Asp(OAll)-NH2 was not observed 
in the crude material by analytical HPLC or LRMS. Also, no evidence of ester 
hydrolysis of diester pyridazine derivatised Fmoc-Asp-NH2 84 by TFA was observed 
in the crude material by analytical HPLC or LRMS. The analogous solid-phase 
synthesis; in situ oxidation and iedDA reaction; and linker cleavage with Fmoc-
Glu(OAll)-OH to give diester pyridazine derivatised Fmoc-Glu-NH2 85 was achieved 
in 86 % overall isolated yield. As expected, no observable differences were 
encountered between the in situ oxidation and iedDA reactions of diester 







Scheme 35. In situ oxidation and iedDA reactions of diester dihydrotetrazine 45 with resin-bound 
Fmoc-Asp(OAll)-OH 83 and Fmoc-Glu(OAll)-OH 86 in the presence of DDQ. Reagents and reaction 
conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; b) i) piperidine in 
DMF, rt, 5 min; ii) Fmoc-Asp(OAll)-OH or Fmoc-Glu(OAll)-OH (3 eq), oxyma (3 eq), DIC (3 eq), 
DMF, rt, 45 min; c) i) diester dihydrotetrazine 45 (1.05 eq), DDQ (3 eq), DCM, rt, 4 h; ii) 
TFA:TIS:DCM (90:5:5), rt, 3 h. 
 
5.5. Unsuccessful Synthesis of Resin-Bound Dihydro-1,2,4,5-tetrazine 
Derivatised Amino Acid 
 
The 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) protecting group was 
developed as a novel amine protecting group which is orthogonal to both the Fmoc 
and tert-butyloxycarbonyl (Boc) protecting groups.126 However, Fmoc deprotection 
occurs during the reported Dde deprotection procedure with hydrazine. Therefore, an 
alternative Dde deprotection procedure was reported within the literature which uses 
NH2OH.HCl:imidazole to ensure full orthogonality between the Dde and Fmoc 
protecting groups.127 Fmoc-Lys(Dde)-OH was selected for the late stage incorporation 
of the dihydro-1,2,4,5-tetrazine moiety onto the peptide backbone as it was 
commercially available; and due to the orthogonality of the Dde protecting group to 




The established synthesis of Dde-OH 87 was developed to enable novel variants of the 
Dde protecting group to be synthesised with increased stability towards piperidine 
which also overcome N-to-N` intramolecular migration.128,129 The acylation of 
cycloalkane diketone 88 with acetic acid in the presence of 4-(dimethylamino)pyridine 
(DMAP) and N-(3-dimethylaminopropyl)-N`-ethylcarbodiimide hydrochloride (EDC) 
to give Dde-OH 87 was reported at 84 % yield. Upon following the literature procedure 
Dde-OH 87 was isolated in 80 % yield (Scheme 36). The condensation of Dde-OH 87 
with Fmoc-Lys-OH hydrochloride in the presence of DIPEA to give Fmoc-Lys(Dde)-




Scheme 36. Synthesis of Fmoc-Lys(Dde)-OH 89. Reagents and reaction conditions a) DMAP (1.05 
eq), EDC (1.05 eq), AcOH (1.05 eq), DMF, rt, 1 d;129 b) Fmoc-Lys-OH.HCl (0.67 eq), DIPEA (1 eq), 
MeOH, rt, ~18 h. 
 
The first attempted syntheses of resin-bound diester dihydrotetrazine derivatised 
amino acids were based on the bisamidation of diester dihydrotetrazine 45 with 
primary or secondary amines which had been reported within the literature.20 The resin 
functionalisation of amino polystyrene resin 77 with Rink amide linker in the presence 
of oxyma and DIC gave Rink amide polystyrene resin 76 (Scheme 37). Successive 
Fmoc deprotection of Rink amide polystyrene resin 76 with piperidine and subsequent 
amino acid coupling of Fmoc-Lys(Dde)-OH 89 in the presence of oxyma and DIC 
gave resin-bound Fmoc-Lys(Dde)-OH 90. The Dde deprotection of resin-bound 
Fmoc-Lys(Dde)-OH 90 with NH2OH.HCl:imidazole and subsequent amidation of 
diester dihydrotetrazine 45 with resin-bound Fmoc-Lys-OH was proposed to give 
resin-bound diester dihydrotetrazine derivatised Fmoc-Lys-OH 91. However, 
complete amidation was not observed based on the qualitative ninhydrin test even after 
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2 d at reflux in DMF with 6 eq of diester dihydrotetrazine 45. Again, complete 
amidation was not observed based on the qualitative ninhydrin test for the analogous 
solid-phase synthesis and amidation with Fmoc-Gly-OH (Appendix 2). Therefore, no 
further attempts were made to synthesise resin-bound diester dihydrotetrazine 
derivatised amino acids based on the bisamidation of diester dihydrotetrazine 45 with 




Scheme 37. Unsuccessful synthesis of resin-bound diester dihydrotetrazine derivatised Fmoc-Lys-OH 
91. Reagents and reaction conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 
45 min; b) i) piperidine in DMF, rt, 5 min; ii) Fmoc-Lys(Dde)-OH 89 (3 eq), oxyma (3 eq), DIC (3 
eq), DMF, rt, 45 min; c) i) NH2OH.HCl:imidazole (1:0.75) in DCM:NMP, rt, 3 h; ii) diester 
dihydrotetrazine 43 (6 eq), DMF, reflux, 2 d. 
 
The last attempted syntheses of resin-bound diester dihydrotetrazine derivatised amino 
acids were based on the coupling of amino acids. The Dde deprotection of resin-bound 
Fmoc-Lys(Dde)-OH 90 with NH2OH.HCl:imidazole and subsequent coupling of 
dicarboxylic acid dihydrotetrazine 48 with resin-bound Fmoc-Lys-OH in the presence 
of oxyma and DIC; and esterification of the second activated carboxylic acid with 
methanol in the presence of DIPEA was proposed to give resin-bound diester 
dihydrotetrazine derivatised Fmoc-Lys-OH 91 (Scheme 38). However, complete 
coupling of dicarboxylic acid dihydrotetrazine 48 was not observed based on the 
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qualitative ninhydrin test even after four coupling attempts. Again, complete coupling 
was not observed based on the qualitative ninhydrin test for the analogous solid-phase 
synthesis, coupling and esterification with Fmoc-Gly-OH (Appendix 3). Therefore, no 
further attempts were made to synthesise resin-bound diester dihydrotetrazine 




Scheme 38. Unsuccessful synthesis of resin-bound diester dihydrotetrazine derivatised Fmoc-Lys-OH 
91. Reagents and reaction conditions a) i) NH2OH.HCl:imidazole (1:0.75) in DCM:NMP, rt, 3 h; ii) 
dicarboxylic acid dihydrotetrazine 48 (3 eq), oxyma (6 eq), DIC (6 eq), DMF, rt, 45 min; iii) 
DCM:DIPEA:MeOH (80:5:15), rt, 45 min. 
 
5.6. Alternative Dihydro-1,2,4,5-tetrazine 
 
Qualitative screening studies of the reactivity of a library of 1,2,4,5-tetrazines with a 
library of dienophiles were conducted to identify candidate 1,2,4,5-tetrazine-
dienophile pairs for the solid-phase thermal activation peptide macrocyclisation 
strategy (Appendix 4-8). However, dipyridyl tetrazine 92 fulfilled the requirements as 
an alternative dihydro-1,2,4,5-tetrazine for the solid-phase oxidation activation peptide 
macrocyclisation strategy. The iedDA reaction of dipyridyl tetrazine 92 with endo-
BCN-OH 60 had gone to completion within 15 min as indicated by the loss of purple 
colour from dipyridyl tetrazine 92. To corroborate the qualitative result endo-dipyridyl 
tricyclopyridazine alcohol 93 was isolated in 94 % yield (Scheme 39A). The oxidation 
of amino dipyridyl dihydrotetrazine 94 with DDQ to give amino dipyridyl tetrazine 95 
has been reported at 81 % yield (Scheme 39B).75 Also, the amine group of amino 
dipyridyl dihydrotetrazine 94 provides a functional handle which can be used for the 
late stage incorporation of amino dipyridyl dihydrotetrazine 94 onto the peptide 
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backbone.81 Therefore, amino dipyridyl dihydrotetrazine 94 was selected as an 
alternative dihydro-1,2,4,5-tetrazine for future development of the solid-phase 




Scheme 39A. iedDA reaction of dipyridyl tetrazine 92 with endo-BCN-OH 60. Reagents and reaction 
conditions a) endo-BCN-OH 60 (1.05 eq), DCM, rt, 2 h. Scheme 39B. Reported synthesis of amino 




The aims of this chapter were to transfer the optimised in situ oxidation and iedDA 
reactions of diester dihydrotetrazine 45 to solid-phase and to verify the in situ 
oxidation and iedDA reactions of resin-bound diester dihydrotetrazine derivatised 
amino acids in the presence of DDQ so that peptide macrocyclisations can be 
conducted on solid-phase. 
 
Commercially available Nα-Fmoc protected standard proteinogenic amino acids were 
selected for the investigation into the stability of resin-bound amino acids towards 
DDQ as these are commonly used amino acids in SPPS and therefore to be used for 
peptide macrocyclisation. No decomposition of resin-bound Fmoc-Aaa-OH 78 by 
DDQ was observed by analytical HPLC for the standard proteinogenic amino acids 
with a protected reactive functional group in their side chain (Scheme 40). However, 
57 
 
insignificant decomposition or oxidation of resin-bound Fmoc-Met-OH by DDQ was 




Scheme 40. Investigation into the stability of resin-bound amino acids towards DDQ. Reagents and 
reaction conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; b) i) 
piperidine in DMF, rt, 5 min; ii) Fmoc-Aaa-OH (3eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; c) 
i) DDQ (3 eq), DCM, rt, 8 h; ii) TFA:TIS:DCM (90:5:5), rt, 1 h. 
 
The in situ oxidation and iedDA reactions of diester dihydrotetrazine 45 with resin-
bound Fmoc-Lys(endo-BCN)-OH 81, Fmoc-Asp(OAll)-OH 83 and Fmoc-Glu(OAll)-
OH 86 in the presence of DDQ to give endo-diester tricyclopyridazine derivatised 
Fmoc-Lys-NH2 82, diester pyridazine derivatised Fmoc-Asp-NH2 84 and diester 
pyridazine derivatised Fmoc-Glu-NH2 85 were achieved in 87, 95 and 86 % isolated 
yield respectively (Scheme 41). Therefore, the optimised in situ oxidation and iedDA 


















Scheme 41. In situ oxidation and iedDA reactions of diester dihydrotetrazine 45 with resin-bound 
Fmoc-Lys(endo-BCN)-OH 81, Fmoc-Asp(OAll)-OH 83 and Fmoc-Glu(OAll)-OH 86 in the presence 
of DDQ. Reagents and reaction conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), 
DMF, rt, 45 min; b) i) piperidine in DMF, rt, 5 min; ii) Fmoc-Lys(endo-BCN)-OH 75, Fmoc-
Asp(OAll)-OH or Fmoc-Glu(OAll)-OH (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; c) i) 
diester dihydrotetrazine 45 (1.05 eq), DDQ (3 eq), DCM, rt, 4 h; ii) TFA:TIS:DCM (90:5:5), rt, 3 h. 
 
The late stage incorporation of diester dihydrotetrazine 45 onto the peptide backbone 
was not successfully verified due to unsuccessful attempts to synthesise resin-bound 
diester dihydrotetrazine derivatised amino acids. 
 
The in situ oxidation and iedDA reactions of resin-bound diester dihydrotetrazine 
derivatised amino acids in the presence of DDQ were not successfully verified due to 
unsuccessful attempts to synthesise resin-bound diester dihydrotetrazine derivatised 
amino acids. The oxidation of amino dipyridyl dihydrotetrazine 94 with DDQ to give 
amino dipyridyl tetrazine 95 has been reported at 81 % yield.75 Also, the amine group 
of amino dipyridyl dihydrotetrazine 94 provides a functional handle which can be used 
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for the late stage incorporation of amino dipyridyl dihydrotetrazine 94 onto the peptide 
backbone.81 Therefore, amino dipyridyl dihydrotetrazine 94 was selected as an 
alternative dihydro-1,2,4,5-tetrazine for future development of the solid-phase 
oxidation activation peptide macrocyclisation strategy.
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The aim of this thesis was to develop a novel solid-phase peptide macrocyclisation 
strategy based on the iedDA reaction of 1,2,4,5-tetrazines. A solid-phase peptide 
macrocyclisation strategy was selected due to their amenability to automated and 
combinatorial synthesis; and efficiency and simplicity over solution-phase 
strategies.87-89 Also, the pseudodilution effect can be exploited to favour 
intramolecular over intermolecular reactions in a solid-phase peptide macrocyclisation 
strategy.90-92 The iedDA reaction of 1,2,4,5-tetrazines was selected due to its 
efficiency, orthogonality, tunability and versatility as shown by its successful 
application in numerous fields of research.69,75,76,79-86 
 
It was decided to use an orthogonal deprotection strategy to enable late stage 
incorporation of the 1,2,4,5-tetrazine moiety onto the peptide backbone due to the then 
unknown stability of 1,2,4,5-tetrazines towards the deprotection, coupling and 
cleavage cycles of SPPS (Scheme 42A).93 A strategy was required to prevent any 
undesired iedDA reaction during the late stage incorporation of the 1,2,4,5-tetrazine 
moiety onto the peptide backbone in the presence of a dienophile. The solid-phase 
thermal activation peptide macrocyclisation strategy was proposed to prevent any 
undesired iedDA reaction during the late stage incorporation of the 1,2,4,5-tetrazine 
moiety onto the peptide backbone in the presence of a dienophile (Scheme 42B). 
However, the fine balance of reaction rates required for selective late stage 
incorporation of the 1,2,4,5-tetrazine moiety onto the peptide backbone in the presence 
of a dienophile and complete control over peptide macrocyclisation would be difficult 
to realise. Therefore, the solid-phase oxidation activation peptide macrocyclisation 
strategy was selected over the solid-phase thermal activation peptide macrocyclisation 
strategy (Scheme 42C). The solid-phase oxidation activation peptide macrocyclisation 
strategy enables selective late stage incorporation of the dihydro-1,2,4,5-tetrazine 
moiety onto the peptide backbone in the presence of a dienophile and complete control 




Scheme 42A. Orthogonal deprotection strategy to enable late stage incorporation of the 1,2,4,5-
tetrazine moiety onto the peptide backbone. Scheme 42B. Solid-phase thermal activation peptide 
macrocyclisation strategy. Scheme 42C. Solid-phase oxidation activation peptide macrocyclisation 
strategy. 
 
To successfully develop a novel solid-phase peptide macrocyclisation strategy based 
on the in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine several 
prerequisites needed to be achieved. Firstly, a proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine needed to be conducted to determine the 
viability of the solid-phase oxidation activation peptide macrocyclisation strategy 
(Scheme 43A). Secondly, optimisation of the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine would be required before transferring 
62 
 
the optimised in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine to 
solid-phase and verifying the in situ oxidation and iedDA reactions of resin-bound 
dihydro-1,2,4,5-tetrazine derivatised amino acids (Schemes 43B and 43C 
respectively). Finally, peptide macrocyclisations needed to be conducted to determine 





Scheme 43A. In situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine. Scheme 43B. In 
situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine transferred to solid-phase. Scheme 
43C. In situ oxidation and iedDA reaction of a resin-bound dihydro-1,2,4,5-tetrazine derivatised 
amino acid. 
 
Diester dihydrotetrazine 45 was selected for the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine as its synthesis had been previously 
reported within the literature;22 it can be readily oxidised to the reactive diester 
tetrazine 46 with isopentyl nitrite which is amenable to SPPS;80 and the amidation of 
diester dihydrotetrazine 45 with primary or secondary amines can be used for the late 
stage incorporation of diester dihydrotetrazine 45 onto the peptide backbone. (E)- 
Cycloalkyne 60 was selected as the model dienophile for the proof of concept in situ 
oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine due to its improved 
isolated yield over the analogous iedDA reactions of diester tetrazine 46 with (Z)-
bicycloalkene 51 and (E)-cycloalkene 49. The in situ oxidation and iedDA reaction of 
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diester dihydrotetrazine 45 with cycloalkyne 50 in the presence of isopentyl nitrite to 
give diester bicyclopyridazine 59 was achieved in quantitative proton NMR yield 
(Scheme 44). Therefore, a successful proof of concept in situ oxidation and iedDA 
reaction of a dihydro-1,2,4,5-tetrazine was achieved. However, the in situ oxidation 
and iedDA reaction of diester dihydrotetrazine 45 with cycloalkyne 50 in the presence 





Scheme 44. In situ oxidation and iedDA reaction of diester dihydrotetrazine 45 with cycloalkyne 50 
in the presence of isopentyl nitrite. Reagents and reaction conditions a) cycloalkyne 50 (1.05 eq), 
isopentyl nitrite (25 eq), DCM, rt, 2 h. 
 
Two strategies were proposed to overcome the poor stability of a strained dienophile 
towards an oxidant and therefore optimise the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine. Firstly, an alternative oxidant which 
does not facilitate decomposition of a strained dienophile can overcome the poor 
stability of a strained dienophile towards an oxidant. DDQ, BTI and PTAD were 
selected as alternative oxidants to optimise the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine due to their corroborated quantitative 
qNMR yields in the oxidation of diester dihydrotetrazine 45. Secondly, an unstrained 
dienophile which is stable to decomposition by an oxidant can overcome the poor 
stability of a strained dienophile towards an oxidant. endo-BCN-OH 60 and allyl ester 
63 were selected as dienophiles to optimise the proof of concept in situ oxidation and 
iedDA reaction of a dihydro-1,2,4,5-tetrazine due to their corroborated quantitative 
and near quantitative qNMR yield respectively in the iedDA reactions of diester 
tetrazine 46. The in situ oxidation and iedDA reactions of diester dihydrotetrazine 45 
with endo-BCN-OH 60 and allyl ester 63 in the presence of DDQ to give endo-diester 
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tricyclopyridazine alcohol 70 and diester pyridazine ester 74 were achieved in 97 % 
and quantitative qNMR yield respectively (Scheme 45). Therefore, the proof of 
concept in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine was 
successfully optimised in the presence of an alternative oxidant and with an unstrained 




Scheme 45. In situ oxidation and iedDA reactions of diester dihydrotetrazine 45 with endo-BCN-OH 
60 and allyl ester 63 in the presence of DDQ. Reagents and reaction conditions a) durene (0.5 eq), 
endo-BCN-OH 60 or allyl ester 63 (1.05 eq), DDQ (3 eq), DCM-d2, 25 °C, 2 h. a Diester pyridazine 
ester 74 was isolated in 97 % yield. 
 
The stability of resin-bound amino acids towards DDQ were determined before 
transferring the optimised in situ oxidation and iedDA reactions of diester 
dihydrotetrazine 45 to solid-phase and verifying the in situ oxidation and iedDA 
reactions of resin-bound diester dihydrotetrazine derivatised amino acids in the 
presence of DDQ. No decomposition of resin-bound Fmoc-Aaa-OH 78 by DDQ was 
observed by analytical HPLC for the standard proteinogenic amino acids with a 
protected reactive functional group in their side chain (Scheme 46A). However, 
insignificant decomposition or oxidation of resin-bound Fmoc-Met-OH by DDQ was 
observed by analytical HPLC. The in situ oxidation and iedDA reactions of diester 
dihydrotetrazine 45 with resin-bound Fmoc-Lys(endo-BCN)-OH 81, Fmoc-
Asp(OAll)-OH 83 and Fmoc-Glu(OAll)-OH 86 in the presence of DDQ to give endo-
diester tricyclopyridazine derivatised Fmoc-Lys-NH2 82, diester pyridazine 
derivatised Fmoc-Asp-NH2 84 and diester pyridazine derivatised Fmoc-Glu-NH2 85 
were achieved in 87, 95 and 86 % isolated yield respectively (Scheme 46B). Therefore, 
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the optimised in situ oxidation and iedDA reactions of diester dihydrotetrazine 45 were 
successfully transferred to solid-phase. However, the in situ oxidation and iedDA 
reactions of resin-bound diester dihydrotetrazine derivatised amino acids in the 
presence of DDQ were not successfully verified due to unsuccessful attempts to 




Scheme 46A. Investigation into the stability of resin-bound amino acids towards DDQ. Reagents and 
reaction conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; b) i) 
piperidine in DMF, rt, 5 min; ii) Fmoc-Aaa-OH (3eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; c) 
i) DDQ (3 eq), DCM, rt, 8 h; ii) TFA:TIS:DCM (90:5:5), rt, 1 h. Scheme 46B. In situ oxidation and 
iedDA reactions of diester dihydrotetrazine 45 with resin-bound Fmoc-Lys(endo-BCN)-OH 81, 
Fmoc-Asp(OAll)-OH 83 and Fmoc-Glu(OAll)-OH 86 in the presence of DDQ. Reagents and reaction 
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conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; b) i) piperidine in 
DMF, rt, 5 min; ii) Fmoc-Lys(endo-BCN)-OH 75, Fmoc-Asp(OAll)-OH or Fmoc-Glu(OAll)-OH (3 
eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; c) i) diester dihydrotetrazine 45 (1.05 eq), DDQ (3 
eq), DCM, rt, 4 h; ii) TFA:TIS:DCM (90:5:5), rt, 3 h. 
 
In conclusion, a successful proof of concept in situ oxidation and iedDA reaction of a 
dihydro-1,2,4,5-tetrazine was achieved which determined the viability of the solid-
phase oxidation activation peptide macrocyclisation strategy. The proof of concept in 
situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine was successfully 
optimised before successfully transferring the optimised in situ oxidation and iedDA 
reactions of a dihydro-1,2,4,5-tetrazine to solid-phase. However, the in situ oxidation 
and iedDA reactions of resin-bound diester dihydrotetrazine derivatised amino acids 
in the presence of DDQ were not successfully verified due to unsuccessful attempts to 
synthesise resin-bound diester dihydrotetrazine derivatised amino acids. Therefore, no 
peptide macrocyclisations were conducted to determine the scope and limitations of 
the solid-phase oxidation activation peptide macrocyclisation strategy. 
 
An electrochemical strategy to selectively trigger the iedDA reaction of a 1,2,4,5-
tetrazine has been previously reported within the literature (Scheme 47A).130 However, 
a non-electrochemical strategy to selectively trigger the iedDA reaction of a 1,2,4,5-
tetrazine has not been reported within the literature. The in situ oxidation and iedDA 
reaction of a dihydro-1,2,4,5-tetrazine methodology reported in this thesis currently 
provides the only non-electrochemical strategy to selectively trigger the iedDA 
reaction of a 1,2,4,5-tetrazine (Scheme 47B). The non-electrochemical strategy to 
selectively trigger the iedDA reaction of a 1,2,4,5-tetrazine could find applications in 
material, polymer and supramolecular chemistry. However, careful selection of the 
dihydro-1,2,4,5-tetrazine, dienophile and oxidant would be required for successful 
application of the non-electrochemical strategy to selectively trigger the iedDA 









Scheme 47A. Electrochemical strategy to selectively trigger the iedDA reaction of a 1,2,4,5-
tetrazine.130 Scheme 47B. Non-electrochemical strategy to selectively trigger the iedDA reaction of a 
1,2,4,5-tetrazine. 
 
6.2. Future Work 
 
To successfully develop a novel solid-phase peptide macrocyclisation strategy based 
on the in situ oxidation and iedDA reaction of a dihydro-1,2,4,5-tetrazine several 
prerequisites still need to be achieved. 
 
Firstly, the solid-phase in situ oxidation and iedDA reactions of diester 
dihydrotetrazine 45 with resin-bound Fmoc-Lys(endo-BCN)-OH 81; and Fmoc-
Asp(OAll)-OH 83 and Fmoc-Glu(OAll)-OH 86 in the presence of DDQ need to be 
repeated with amino dipyridyl dihydrotetrazine 94 to verify the solid-phase in situ 
oxidation and iedDA reactions of amino dipyridyl dihydrotetrazine 94 (Schemes 48A 
and 48B respectively). The oxidation of amino dipyridyl dihydrotetrazine 94 with 














Scheme 48A. Proposed in situ oxidation and iedDA reaction of amino dipyridyl dihydrotetrazine 94 
with resin-bound Fmoc-Lys(endo-BCN)-OH 81 in the presence of DDQ. Reagents and reaction 
conditions a) i) amino dipyridyl dihydrotetrazine 94 (1.05 eq), DDQ (3 eq), DCM, rt, 4 h; ii) 
TFA:TIS:DCM (90:5:5), rt, 3 h. Scheme 48B. Proposed in situ oxidation and iedDA reaction of 
amino dipyridyl dihydrotetrazine 94 with Fmoc-Asp(OAll)-OH 83 and Fmoc-Glu(OAll)-OH 86 in the 
presence of DDQ. Reagents and reaction conditions a) i) amino dipyridyl dihydrotetrazine 94 (1.05 
eq), DDQ (3 eq), DCM, rt, 4 h; ii) TFA:TIS:DCM (90:5:5), rt, 3 h. Scheme 48C. Reported synthesis 
of amino dipyridyl tetrazine 95. Reagents and reaction conditions a) DDQ (2 eq), toluene, reflux, 12 h, 
N2.75 
 
Secondly, resin-bound amino dipyridyl dihydrotetrazine derivatised amino acids need 
to be synthesised to verify the late stage incorporation of amino dipyridyl 
dihydrotetrazine 94 onto the peptide backbone. The amine group of amino dipyridyl 
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dihydrotetrazine 94 provides a functional handle which can be used for the late stage 
incorporation of amino dipyridyl dihydrotetrazine 94 onto the peptide backbone.81 The 
amidation of glutaric anhydride with amino dipyridyl dihydrotetrazine 94 has been 
reported to give carboxylic acid dipyridyl dihydrotetrazine 96 at 65 % yield (Scheme 
49A). The amidation of carboxylic acid dipyridyl dihydrotetrazine 96 with primary 
and secondary amines in the presence oxyma and DIC was proposed to give resin-
bound amino dipyridyl dihydrotetrazine derivatised amino acids (Scheme 49B). 
Therefore, the amidation of carboxylic acid dipyridyl dihydrotetrazine 96 with primary 
and secondary amines in the presence oxyma and DIC was selected for the synthesis 




Scheme 49A. Reported synthesis of carboxylic acid dipyridyl dihydrotetrazine 96. Reagents and 
reaction conditions a) glutaric anhydride (5 eq), THF, reflux, 20 h. Scheme 49B. Proposed synthesis 
of resin-bound amino dipyridyl dihydrotetrazine derivatised amino acids. Reagents and reaction 
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conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; b) i) piperidine in 
DMF, rt, 5 min; ii) Fmoc-Aaa-OH (3eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 45 min; c) i) piperidine 
in DMF, rt, 5 min; ii) carboxylic acid dipyridyl dihydrotetrazine 96 (3 eq), oxyma (6 eq), DIC (6 eq), 
DMF, rt, 45 min. 
 
Thirdly, the in situ oxidation and iedDA reactions of resin-bound amino dipyridyl 
dihydrotetrazine derivatised amino acids with Fmoc-Lys(endo-BCN)-OH 75, Fmoc-
Asp(OAll)-OH and Fmoc-Glu(OAll)-OH in the presence of DDQ need to be 
conducted to verify the in situ oxidation and iedDA reactions of resin-bound amino 




Scheme 50. Proposed in situ oxidation and iedDA reactions of resin-bound amino dipyridyl 
dihydrotetrazine derivatised amino acid with Fmoc-Lys(endo-BCN)-OH 75, Fmoc-Asp(OAll)-OH 
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and Fmoc-Glu(OAll)-OH in the presence of DDQ. Reagents and reaction conditions a) i) Fmoc-
Lys(endo-BCN)-OH 75, Fmoc-Asp(OAll)-OH and Fmoc-Glu(OAll)-OH (1.05 eq), DDQ (3 eq), 
DCM, rt, 4 h; ii) TFA:TIS:DCM (90:5:5), rt, 3 h. 
 
Finally, peptide macrocyclisations need to be conducted to determine the scope and 
limitations of the solid-phase oxidation activation peptide macrocyclisation strategy. 
 
Potential research projects which have arisen from the work presented in this thesis 
include research projects to develop the non-electrochemical strategy to selectively 




Chapter 7. Experimental 
 




All commercially available solvents and reagents were used as obtained from the 
supplier unless otherwise stated. Distilled water was obtained from an ELGA Option 
3 Water Purification System. Anhydrous acetonitrile, DCM, diethyl ether, methanol 





Non-anhydrous solution-phase synthesis was conducted using standard laboratory 
glassware and equipment; and standard non-anhydrous techniques. Anhydrous 
solution-phase synthesis was conducted using oven dried laboratory glassware, 
standard laboratory equipment and standard anhydrous techniques under a positive 




Solid-phase synthesis was conducted using column reservoirs fitted with polyethylene 
frits and Teflon stopcocks; GL Biochem Aminomethyl Polystyrene Resin (100-200 
Mesh, 0.3-0.8 mmolg-1, 1 % DVB); standard laboratory equipment; and standard solid-
phase techniques. Amino acid couplings were tested for completion using a modified 
version of the qualitative ninhydrin test.131 Solution A (3 drops) and solution B (1 drop) 
were added to a few beads of resin at rt. The resin was maintained at 110 °C for 3 min. 
Solution A was prepared by adding potassium cyanide (1.30 mg) in water (2 mL), 
ethanol (10 mL) and phenol (40 mL) to freshly distilled pyridine (100 mL) at rt. 






Thin-layer chromatography (TLC) was conducted using Merck TLC Silica Gel 60 F254 
Plates and visualised by eye; potassium permanganate and heating; or short wave 
ultraviolet light (254 nm). Potassium permanganate stain was prepared by adding 
potassium permanganate (1.50 g), potassium carbonate (10.0 g) and sodium hydroxide 
solution (1.25 mL, 3 M aq) to water (200 mL) at rt. 
 
Flash column chromatography was conducted using Merck Silica Gel 60 according to 
the procedure of Still et al.132 The crude products were dry loaded onto the column 
using Fisher Chemical General Purpose Grade Kieselguhr Washed with Acid then 
eluted using an isocratic solvent system or a step graduated solvent system with 
increasing solvent polarity. 
 
Automated flash column chromatography was conducted using a Teledyne Isco 
CombiFlash Rf Flash Chromatography System with detection at 254 and 280 nm; and 
Teledyne RediSep Rf Normal-Phase Silica Columns. The crude products were dry 
loaded onto the column using Sigma Aldrich Filter Agent then eluted using an isocratic 




Melting points were recorded in open capillary tubes using a Gallenkamp Melting 




Infrared (IR) spectra were recorded using a Bruker Tensor 27 FT-IR Spectrometer 
fitted with a Specac Golden Gate Single Reflection Diamond ATR Attachment or a 
Perkin Elmer Spectrum 65 FT-IR Spectrometer fitted with a PIKE MIRacle single 
reflection ZnSe Crystal Plate. Each spectrum was recorded with a scan range of 4500-
500 cm-1 using 16 background scans of a clean crystal plate and 32 scans of sample at 
74 
 
4 cm-1 resolution. Only frequencies corresponding to significant functional groups are 
reported. 
 
Nuclear Magnetic Resonance Spectroscopy 
 
Proton NMR spectra were recorded at 25 degree Celsius (°C) using an automated 
Bruker Ascend 500 MHz Spectrometer fitted with a Bruker DCH-ATMA CryoProbe, 
an automated Bruker Ascend 500 MHz Spectrometer fitted with a Bruker Prodigy 
BBO CryoProbe, an automated Bruker Avance I 400 MHz Spectrometer fitted with a 
Bruker BBI Probe, an automated Bruker Avance I 400 MHz Spectrometer fitted with 
a Bruker QNP Probe, an automated Bruker Avance III 400 MHz Spectrometer fitted 
with a Bruker BBFO-ATMA Probe, an automated Bruker Avance III 400 MHz 
Spectrometer fitted with a Bruker PABBO-BB Probe or an automated Bruker Avance 
III 500 MHz Spectrometer fitted with a Bruker DCH-ATMA CryoProbe in deuterated 
chloroform, deuterated dichloromethane (DCM-d2) or deuterated dimethyl sulfoxide 
(DMSO-d6) using residual non-deuterated solvent as the internal reference. The 
chemical shifts are reported in parts per million (ppm). 
 
Carbon NMR spectra were recorded at 25 °C using an automated Bruker Ascend 500 
MHz Spectrometer fitted with a Bruker DCH-ATMA CryoProbe, an automated Bruker 
Avance I 400 MHz Spectrometer fitted with a Bruker QNP Probe, an automated 
Bruker Avance III 400 MHz Spectrometer fitted with a Bruker PABBO-BB Probe or 
an automated Bruker Avance III 500 MHz Spectrometer fitted with a Bruker DCH-
ATMA CryoProbe in deuterated chloroform or DMSO-d6 using deuterated solvent as 
the internal reference. The chemical shifts are reported in ppm. 
 
qNMR yields were calculated from separated peaks in proton NMR spectra recorded 
without any modifications to the open access proton NMR experimental parameters 












× 𝑛𝑖𝑛𝑡  
𝑛𝑎𝑛𝑎𝑙 = number of moles of analyte 
𝐼𝑎𝑛𝑎𝑙 = integral of analyte signal 
𝐼𝑖𝑛𝑡 = integral of qNMR internal standard signal 
𝑁𝑖𝑛𝑡 = number of qNMR internal standard protons 
𝑁𝑎𝑛𝑎𝑙 = number of analyte protons 
𝑛𝑖𝑛𝑡 = number of moles of qNMR internal standard 
 




Low-resolution mass spectra were recorded using an Agilent 1100 HPLC Modular 
System coupled to an Agilent Technologies 6130 LC/MS Quadrupole Mass 
Spectrometer, a Bruker MicrOTOF Mass Spectrometer or a Hewlett-Packard 1100 
LC/MSD Quadrupole Mass Spectrometer under electrospray ionisation (ESI) 
conditions; a Thermo Finnigan LCQ Mass Spectrometer under ESI or electron 
ionisation (EI) conditions; or a Thermo Finnigan MAT 900 XLP Mass Spectrometer 
under chemical ionisation (CI), EI, ESI or fast atom bombardment (FAB) conditions. 
 
High-resolution mass spectra were recorded using an Agilent 1100 HPLC Modular 
System coupled to a Bruker MicrOTOF Mass Spectrometer under ESI conditions or a 
Thermo Finnigan MAT 900 XLP Mass Spectrometer under CI, EI or ESI conditions. 
 
High-Performance Liquid Chromatography 
 
Analytical HPLC was conducted using an Agilent Technologies 1100 Series HPLC 
Modular System coupled to a Polymer Laboratories PL-ELS 1000 Evaporative Light 
Scattering Detector and an Agilent Technologies 1100 Series Diode-Array Detector 
with detection at 254, 350, 500, 650 and 750 nm. 
 




Column 2: Supelco Discovery HS C18 HPLC Column, 5 μm, 4.6 × 50 mm. 
 
Column 3: Phenomenex Kinetex XB-C18, 5 μm, 4.6 × 50 mm. 
 
Method A: Gradient 5.0 to 95 % (10 min), isocratic (4 min), gradient 95 to 5.0 % (5 s) 
then isocratic (55 s) at a flow rate of 1 millilitre (mL) per minute using HPLC grade 
acetonitrile with 0.10 % formic acid in HPLC grade water with 0.10 % formic acid. 
 
Method B: Gradient 5.0 to 95 % (10 min), isocratic (4 min), gradient 95 to 5.0 % (5 s) 
then isocratic (55 s) at a flow rate of 1 mLmin-1 using HPLC grade methanol with 0.10 
% formic acid in HPLC grade water with 0.10 % formic acid. 
 
7.2. General Procedures 
 
General Procedure 1: Resin Functionalisation 
 
Resin (1 eq) was swollen in DCM for 5 min then washed with DCM (× 3). Oxyma (3 
eq) was added to a stirring solution of linker (3 eq) at rt in DMF. The reaction mixture 
was stirred for 5 min before adding DIC (3 eq). The reaction mixture was stirred for 2 
min before adding to the resin. The resin was agitated for 45 min then filtered before 
washing with DMF (× 3), DCM (× 3), methanol (× 3) and diethyl ether (× 3). The 
functionalised resin was dried under reduced pressure prior to storage. 
 
General Procedure 2: Fmoc Deprotection and Amino Acid Coupling 
 
Functionalised resin (1 eq) was swollen in DCM for 5 min then washed with DCM (× 
3). Piperidine solution (20 % DMF) was added to the functionalised resin at rt. The 
functionalised resin was agitated for 5 min then filtered before washing with DMF (× 
3) and DCM (× 3). The Fmoc deprotection step was repeated twice. Oxyma (3 eq) was 
added to a stirring solution of Fmoc-Aaa-OH (3 eq) at rt in DMF. The reaction mixture 
was stirred for 5 min before adding DIC (3 eq). The reaction mixture was stirred for 2 
min before adding to the functionalised resin. The functionalised resin was agitated for 
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45 min then filtered before washing with DMF (× 3), DCM (× 3), methanol (× 3) and 
diethyl ether (× 3). The amino acid loaded functionalised resin was dried under reduced 
pressure prior to storage. 
 
General Procedure 3: Linker Cleavage 
 
Amino acid loaded functionalised resin (1 eq) was swollen in DCM for 5 min then 
washed with DCM (× 3). TFA:TIS:DCM (90:5:5) was added to the resin at rt. The 
amino acid loaded functionalised resin was agitated for 1-3 h then filtered before 
washing with TFA (× 3). The combined organic filtrates were concentrated under 
reduced pressure and the residue suspended in cold diethyl ether. The suspension was 
centrifuged then decanted before drying under reduced pressure to give crude product. 
 






Ethyl diazoacetate (4.61 mL, 43.8 mmol, 1 eq) was added dropwise to a stirring 
solution of sodium hydroxide (8.04 g, 0.201 mol, 4.6 eq) in water (12 mL) at rt. The 
reaction mixture was heated to 70 °C and stirred for 1.5 h before cooling to rt. Ethanol 
(50 mL) was added to the reaction mixture. The reaction mixture was stirred for 30 
min before the insoluble solid was removed by filtration. The filtrand was washed with 
ethanol (3 × 20 mL) and diethyl ether (3 × 20 mL) then dried under reduced pressure. 
Hydrochloric acid (9.17 mL, 57 % aq) was added dropwise to a stirring solution of 
filtrand (4.52 g, 20.9 mmol, 1 eq) in water (10 mL) at -10 °C. The insoluble solid was 
immediately removed by filtration and the filtrand resuspended in water (12 mL) at 0 
°C. The suspension was stirred for 30 min before the insoluble solid was removed by 
filtration. The filtrand was washed with cold water (3 × 10 mL) and cold diethyl ether 
(3 × 10 mL) then dried under reduced pressure to give dicarboxylic acid 
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dihydrotetrazine 48 as a yellow solid (1.33 g, 36 %): Rf (DCM:MeOH, 7:3) 0.32; mp 
145-146 °C, literature 144-148 °C;22 IR (neat, cm-1) 3531 (O-H), 3318 (N-H), 1696 
(C=O), 1186 (C-O); 1H NMR δ (500 MHz, DMSO-d6) 8.96 (2H, s, RNHN); 13C NMR 
δ (125 MHz, DMSO-d6) 161.3 (2C, RCO2H), 140.8 (2C, NCNHCO2H); m/z (ESI-, 
DMSO) 170.8 ([M-H]-, 24 %), 126.8 (28), 61.9 (100); HRMS (ESI-, DMSO) not 
observed; HPLC (column 1, method B, ELSD, H2O) tR 1.03 min. 
 




Freshly distilled thionyl chloride (4.24 mL, 59.8 mmol, 2.6 eq) was added dropwise to 
stirring anhydrous methanol (25 mL) at -30 °C under nitrogen. Dicarboxylic acid 
dihydrotetrazine 48 (3.95 g, 23.0 mmol, 1 eq) in anhydrous methanol (32 mL) was 
added dropwise to the thionyl chloride solution. The reaction mixture was heated to 
40 °C and stirred for 2 h before cooling to -30 °C. The insoluble solid was removed by 
filtration and the filtrand washed with cold methanol (3 × 10 mL) and cold diethyl 
ether (3 × 10 mL) before drying under reduced pressure to give crude product. The 
crude product was purified by flash column chromatography eluting with DCM to give 
diester dihydrotetrazine 45 as an orange solid (3.55 g, 77 %): Rf (DCM:MeOH, 19:1) 
0.68; mp 170-171 °C, literature 170-171 °C;22 IR (neat, cm-1) 3359 (N-H), 1720 
(C=O), 1198 (C-O); 1H NMR δ (500 MHz, CDCl3) 7.47 (2H, s, RNHN), 3.92 (6H, s, 
CO2CH3); 13C NMR δ (125 MHz, CDCl3) 159.2 (2C, RCO2R), 138.2 (2C, 
NCNHCO2R), 53.9 (2C, CO2CH3); m/z (ESI+, MeOH) 201.2 ([M+H]
+, 52 %), 222.8 
([M+Na]+, 7 %), 423.2 ([2M+Na]+, 50 %), 127.2 (30), 115.2 (100), 105.2 (34); HPLC 
(column 1, method B, ELSD, MeOH) tR 0.78 min. The spectroscopic data was in 











Isopentyl nitrite (0.505 mL, 3.75 mmol, 3 eq) was added dropwise to a stirring solution 
of diester dihydrotetrazine 45 (0.250 g, 1.25 mmol, 1 eq) in DCM (10 mL) at rt. The 
reaction mixture was stirred for 2 h before the solvent was removed under reduced 
pressure to give crude product. The crude product was purified by recrystallisation in 
DCM:hexane (10:1) to give diester tetrazine 46 as a red solid (0.119 g, 48 %): Rf 
decomposed on TLC plate; mp 174-175 °C, literature 173-175 °C;22 IR (neat, cm-1) 
1745 (C=O), 1206 (C-O); 1H NMR δ (500 MHz, CDCl3) 4.23 (6H, s, CO2CH3); 13C 
NMR δ (125 MHz, CDCl3) 160.5 (2C, NCNCO2R), 159.3 (2C, ArCO2R), 54.8 (2C, 
CO2CH3); m/z (EI, DCM) 198.0 ([M]
+., 54 %), 54.0 (100); HPLC (column 1, method 







cis-Cyclooctene (11.8 mL, 90.7 mmol, 1 eq) was added to a stirring solution of 
mCPBA (22.8 g, 90.7 mmol, 1 eq) in DCM (200 mL) at rt. The reaction mixture was 
stirred for 5 h. The reaction mixture was washed with sodium carbonate solution (3 × 
200 mL, sat aq) and water (3 × 200 mL) then dried over anhydrous magnesium sulfate 
before the solvent was removed under reduced pressure to give crude product. The 
crude product was purified by flash column chromatography eluting with diethyl 
ether:hexane (1:19) to give cycloalkane epoxide 53 as a colourless solid (7.50 g, 65 
%): Rf (Et2O:hexane, 1:19) 0.31; mp 53-54 °C, literature 56-57 °C;
134 IR (neat, cm-1) 
no reportable peaks observed; 1H NMR δ (500 MHz, CDCl3) 2.92-2.88 (2H, m, 
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RCHOR), 2.14-2.12 (2H, m, RCHOCH2R), 1.63-1.40 (8H, m, RCH2R), 1.31-1.23 
(2H, m, RCHOCH2R); 13C NMR δ (125 MHz, CDCl3) 55.8 (2C, RCHOR), 26.7 (2C, 
RCH2R), 26.4 (2C, RCHOCH2R), 25.7 (2C RCH2R); m/z (ESI+, DCM) 127.0 
([M+H]+, 7 %), 149.0 ([M+Na]+, 61 %), 133.0 (26), 119.0 (28), 65.0 (100); HPLC 
(column 1, method B, ELSD, MeOH) tR not observed. The spectroscopic data was in 
agreement with the literature.108 
 




Chlorodiphenylphosphine (16.8 mL, 90.6 mmol, 1 eq) in anhydrous THF (39 mL) was 
added dropwise to lithium wire (1.38 g, 0.199 mol, 2.2 eq) in anhydrous THF (95 mL) 
at rt under nitrogen. The reaction mixture was stirred overnight to give phosphane 






Cycloalkane epoxide 53 (11.3 g, 89.5 mmol, 1 eq) in anhydrous THF (42 mL) was 
added to stirring phosphane solution 97 (146 mL, 98.5 mmol, 1.1 eq) at rt under 
nitrogen. The reaction mixture was stirred for 2 d before acetic acid (6.41 mL, 0.112 
mol, 1.25 eq) and hydrogen peroxide solution (133 mL, 3 % aq) were added dropwise 
at 0 °C. The reaction mixture was warmed to rt and stirred for 1 h before extracting 
with DCM (3 × 300 mL). The combined organic extracts were washed with water (3 
× 300 mL) then dried over anhydrous magnesium sulfate before the solvent was 
removed under reduced pressure to give crude product. The crude product was purified 
by flash column chromatography eluting with DCM to give cycloalkane epoxide 53 
(1.92 g, 17 %). Further elution with DCM:methanol (49:1) gave (±)-trans-alcohol 
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phosphine oxide cycloalkane 54 as a colourless solid (21.1 g, 72 %): Rf (DCM:MeOH, 
49:1) 0.19; mp 160-161 °C, literature 149-150 °C, benzene;108 IR (neat, cm-1) 3248 
(O-H), 1115 (C-O); 1H NMR δ (500 MHz, CDCl3) 7.80-7.71 (4H, m, ArH), 7.60-7.55 
(2H, m, ArH), 7.52-7.48 (4H, m, ArH), 4.34 (1H, br s, ROH), 4.13-4.09 (1H, m, 
RCHOHR), 2.81-2.74 (1H, m, RCHPR), 1.96-1.56 (8H, m, RCH2CHOHR, 
RCHPCH2R and RCH2R), 1.49-1.33 (3H, m, RCH2R), 1.23-1.19 (1H, m, 
RCHPCH2R); 13C NMR δ (125 MHz, CDCl3) 132.8 (2C, d, J 8.4 Hz, ArH), 132.3 
(1C, d, J 2.6 Hz, ArH), 132.3 (1C, d, J 2.6 Hz, ArH), 132.1 (1C, d, J 96.5 Hz, ArP), 
131.3 (2C, d, J 9.1 Hz, ArH), 129.4 (1C, d, J 93.5 Hz, ArP), 128.9 (2C, d, J 11.4 Hz, 
ArH), 128.5 (2C, d, J 11.1 Hz, ArH), 70.5 (1C, d, J 3.5 Hz, RCHOHR), 42.6 (1C, d, J 
67.5 Hz, RCHPR), 30.8 (1C, d, J 12.4 Hz, RCH2CHOHR), 29.0 (1C, d, J 10.6 Hz, 
RCH2R), 27.0 (1C, RCH2R), 25.0 (1C, RCH2R), 24.6 (1C, RCHPCH2R), 21.2 (1C, 
RCH2R); m/z (ESI+, MeCN) 329.2 ([M+H]
+, 32 %), 351.2 ([M+Na]+, 17 %), 657.4 
([2M+H]+, 17 %), 679.4 ([2M+Na]+, 100 %), 146.2 (76), 105.2 (58); HPLC (column 
1, method A, ELSD, MeCN) tR 7.61 min. The spectroscopic data was in agreement 






(±)-trans-Alcohol phosphine oxide cycloalkane 54 (8.42 g, 25.6 mmol, 1 eq) in 
anhydrous DMF (70 mL) was added dropwise to a stirring solution of sodium hydride 
(0.737 g, 30.7 mmol, 1.2 eq) in anhydrous DMF (85 mL) at 0 °C under nitrogen. The 
reaction mixture was warmed to rt and stirred for 3 h before diluting with pentane (200 
mL). The reaction mixture was washed with ammonium chloride solution (1 × 200 
mL, sat aq) and water (3 × 200 mL) then dried over anhydrous magnesium sulfate 
before the solvent was removed under reduced pressure to give crude product. The 
crude product was purified by distillation under reduced pressure to give (E)-
cycloalkene 49 as a colourless oil (1.11 g, 39 %): drE:Z 99:1; Rf (hexane) 0.71; bp 54-
55 °C, 40 mbar, literature 44 °C, 30 mbar;104 IR (neat, cm-1) 1650 (C=C); 1H NMR δ 
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(500 MHz, CDCl3) 5.51-5.46 (2H, m, RCHR), 2.38-2.35 (2H, m, RCHCH2R), 2.00-
1.91 (4H, m, RCHCH2R and RCH2R), 1.86-1.78 (2H, m, RCH2R), 1.47-1.39 (2H, m, 
RCH2R), 0.83-0.76 (2H, m, RCH2R); 13C NMR δ (125 MHz, CDCl3) 134.1 (2C, 
RCHR), 35.9 (2C, RCHCH2R), 35.8 (2C, RCH2R), 29.3 (2C, RCH2R); m/z (EI, 
hexane) 110.1 ([M]+., 39 %), 67.1 (100); HPLC (column 1, method B, ELSD, MeOH) 







Bromine (3.94 mL, 76.8 mmol, 1 eq) was added dropwise to a stirring solution of cis-
cyclooctene (10.0 mL, 76.8 mmol, 1 eq) in DCM (30 mL) at -40 °C. The reaction 
mixture was stirred at -40 °C for 30 min before warming to rt. The reaction mixture 
was washed with sodium thiosulfate solution (1 × 30 mL, sat aq), water (1 × 30 mL) 
and sodium chloride solution (1 × 30 mL, sat aq) then dried over anhydrous 
magnesium sulfate before the solvent was removed under reduced pressure to give 
crude product. The crude product was purified by flash column chromatography 
eluting with hexane to give (±)-trans-dibromocycloalkane 55 as a colourless oil (11.2 
g, 54 %): Rf (hexane) 0.39; IR (neat, cm-1) 696 (C-Br); 1H NMR δ (400 MHz, CDCl3) 
4.61-4.56 (2H, m, RCHBrR), 2.44-2.38 (2H, m, RCHBrCH2R), 2.10-2.05 (2H, m, 
RCHBrCH2R), 1.90-1.81 (2H, m, RCH2R), 1.72-1.55 (4H, m, RCH2R), 1.52-1.45 (2H, 
m, RCH2R); 13C NMR δ (125 MHz, CDCl3) 61.7 (2C, RCHBrR), 33.4 (2C, 
RCHBrCH2R), 26.1 (2C, RCH2R), 25.6 (2C, RCH2R); m/z (CI, hexane) 269.9 
([M+H]+, 76 %), 268.9 (74); HPLC (column 1, method B, ELSD, MeOH) tR not 











1 M Potassium tert-butoxide solution in anhydrous THF (5.55 mL, 5.55 mmol, 1.5 eq) 
was added dropwise to a stirring solution of (±)-trans-dibromocycloalkane 55 (1.00 g, 
3.70 mmol, 1 eq) in anhydrous diethyl ether (1.5 mL) at 0 °C under nitrogen. The 
reaction mixture was warmed to rt and stirred for 1 h before diluting with water (20 
mL). The organic layer was separated from the aqueous (aq) layer and the aq layer 
extracted with diethyl ether (3 × 20 mL). The organic layer and combined organic 
extracts were dried over anhydrous magnesium sulfate before the solvent was removed 
under reduced pressure to give crude product. The crude product was purified by flash 
column chromatography eluting with hexane to give (E)-bromocycloalkene 56 as a 
colourless oil (0.453 g, 65 %): Rf (hexane) 0.63; IR (neat, cm-1) 1642 (C=C); 1H NMR 
δ (400 MHz, CDCl3) 6.03 (1H, t, J 8.5 Hz, RCHR), 2.63-2.60 (2H, m, RCBrCH2R), 
2.10-2.07 (2H, m, RCH2CHR), 1.65-1.61 (2H, m, RCH2R), 1.57-1.50 (6H, m, 
RCH2R); 13C NMR δ (125 MHz, CDCl3) 131.8 (1C, RCHR), 125.0 (1C, RCBrR), 
35.3 (1C, RCBrCH2R), 30.0 (1C, RCH2R), 28.8 (1C, RCH2CHR), 27.6 (1C, RCH2R), 
26.5 (1C, RCH2R), 25.6 (1C, RCH2R); m/z (EI, hexane) 190.0 ([M]
+., 28 %), 188.0 
(29), 109.0 (78), 67.0 (100); HPLC (column 1, method B, ELSD, MeOH) tR not 
observed. The spectroscopic data was in agreement with the literature.136 
 




1.6 M n-Butyllithium solution in anhydrous hexanes (14.5 mL, 23.2 mmol, 0.5 eq) was 
added dropwise to a stirring solution of freshly distilled diisopropylamine (3.38 mL, 
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24.1 mmol, 0.52 eq) in anhydrous THF (11 mL) at -25 °C under nitrogen. LDA 






(E)-Bromocycloalkene 56 (8.78 g, 48.2 mmol, 1 eq) was added to LDA solution 98 
(28.9 mL, 24.1 mmol, 0.5 eq) at -25 °C under nitrogen. The reaction mixture was 
warmed to rt and stirred for 2.5 h before neutralising with hydrochloric acid (35 mL, 
1 M aq). The organic layer was separated from the aq layer and the aq layer extracted 
with hexane (3 × 50 mL). The organic layer and combined organic extracts were 
washed with water (3 × 50 mL) then dried over anhydrous magnesium sulfate before 
the solvent was removed under reduced pressure to give crude product. The crude 
product was purified by distillation under reduced pressure to give cycloalkyne 50 as 
a colourless oil (0.394 g, 16 %): Rf (hexane) 0.81; bp 59-61 °C, 40 mbar, literature 51-
52 °C, 29 mbar;110 IR (neat, cm-1) no reportable peaks observed; 1H NMR δ (500 
MHz, CDCl3) 2.17-2.14 (4H, m, RCCH2R), 1.90-1.82 (4H, m, RCH2R), 1.64-1.60 
(4H, m, RCH2R); 13C NMR δ (125 MHz, CDCl3) 94.9 (2C, RCR), 34.8 (2C, 
RCCH2R), 30.0 (2C, RCH2R), 21.2 (2C, RCH2R); m/z (EI, hexane) 108.1 ([M]
+., 16 
%), 79.1 (100); HPLC (column 1, method B, ELSD, MeOH) tR not observed. The 









Bicyclo[2.2.1]hept-2-ene (37.5 mg, 0.398 mmol, 1.05 eq) was added slowly to a 
stirring solution of diester tetrazine 46 (75.0 mg, 0.379 mmol, 1 eq) in DCM (3.79 mL) 
at rt. The reaction mixture was stirred for 2 h before the solvent was removed under 
reduced pressure to give crude product. The crude product was purified by flash 
column chromatography eluting with ethyl acetate:hexane (1:9) to give diester 
tricyclodihydropyridazine 57 as a colourless solid (79.0 mg, 79 %): Rf (EtOAc:hexane, 
1:3) 0.25; mp 122-123 °C, literature 122-123 °C, MeOH;113 IR (neat, cm-1) 3327 (N-
H), 1695 (C=O), 1138 (C-O); 1H NMR δ (500 MHz, CDCl3) 8.52 (1H, br s, RNHN), 
3.86 (3H, s, CO2CH3), 3.83 (3H, s, CO2CH3), 3.61 (1H, d, J 3.9 Hz, R3CH), 3.51 (1H, 
d, J 4.0 Hz, R3CH), 2.09 (1H, d, J 1.9 Hz, R3CH), 1.90-1.76 (2H, m, RCH2eqR), 1.58-
1.50 (2H, m, RCH2R and RCH2axR), 1.38-1.33 (1H, m, RCH2axR), 1.19-1.16 (1H, m, 
RCH2R); 13C NMR δ (125 MHz, CDCl3) 164.3 (1C, RCO2R), 162.1 (1C, RCO2R), 
132.4 (1C, NCRCO2R), 128.7 (1C, RCNHCO2R), 121.1 (1C, R3C), 52.4 (1C, 
CO2CH3), 52.4 (1C, CO2CH3), 43.5 (1C, R3CH), 42.3 (1C, RCH2R), 41.4 (1C, R3CH), 
37.6 (1C, R3CH), 29.0 (1C, RCH2R), 26.4 (1C, RCH2R); m/z (ESI+, MeCN) 265.2 
([M+H]+, 17 %), 287.1 ([M+Na]+, 13 %), 529.3 ([2M+H]+, 13 %), 551.2 ([2M+Na]+, 
100 %); HPLC (column 1, method A, ELSD, MeCN) tR 6.72 min. The spectroscopic 







(E)-Cycloalkene 49 (61.8 mg, 0.561 mmol, 1.05 eq) was added dropwise to a stirring 
solution of diester tetrazine 46 (0.106 g, 0.534 mmol, 1 eq) in DCM (5.34 mL) at rt. 
The reaction mixture was stirred for 2 h before the solvent was removed under reduced 
pressure to give crude product. The crude product was purified by flash column 
chromatography eluting with ethyl acetate:hexane (1:9) to give diester 
bicyclodihydropyridazine 58 as a colourless solid (0.111g, 74 %): Rf (EtOAc:hexane, 
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1:3) 0.30; mp 104-105 °C, literature 107 °C, H2O:MeOH;
59 IR (neat, cm-1) 3351 (N-
H), 1722 (C=O), 1695 (C=O), 1255 (C-O); 1H NMR δ (500 MHz, CDCl3) 8.58 (1H, 
br s, RNHN), 3.86 (3H, s, CO2CH3), 3.85 (3H, s, CO2CH3), 3.82-3.79 (1H, m, R3CH), 
3.45 (1H, ddd, J 16.0, 10.5 and 3.3 Hz, RCH2axCR2), 2.10 (1H, ddd, J 16.0, 7.4 and 
3.3 Hz, RCH2eqCR2), 2.00-1.91 (1H, m, RCH2R), 1.75-1.56 (5H, m, RCH2R), 1.45-
1.34 (4H, m, RCH2R); 13C NMR δ (125 MHz, CDCl3) 164.7 (1C, RCO2R), 162.5 (1C, 
RCO2R), 132.7 (1C, NCRCO2R), 128.7 (1C, RCNHCO2R), 124.8 (1C, R3C), 52.7 (1C, 
CO2CH3), 52.4 (1C, CO2CH3), 36.0 (1C, R3CH), 31.4 (1C, RCH2CR2), 29.7 (1C, 
RCH2R), 28.7 (1C, RCH2R), 26.4 (1C, RCH2R), 24.0 (1C, RCH2R), 23.7 (1C, 
RCH2R); m/z (ESI+, MeCN) 281.2 ([M+H]
+, 7 %), 303.2 ([M+Na]+, 19 %), 583.2 
([2M+Na]+, 100 %); HRMS (ESI+, MeCN) [M+H]+ found 281.1492 (C14H21N2O4 







Cycloalkyne 50 (61.2 mg, 0.566 mmol, 1.05 eq) was added dropwise to a stirring 
solution of diester tetrazine 46 (0.107 g, 0.539 mmol, 1 eq) in DCM (5.39 mL) at rt. 
The reaction mixture was stirred for 2 h before the solvent was removed under reduced 
pressure to give crude product. The crude product was purified by flash column 
chromatography eluting with ethyl acetate:hexane (1:3) to give diester 
bicyclopyridazine 59 as a colourless solid (0.138 g, 92 %): Rf (EtOAc:hexane, 1:3) 
0.26; mp 85-87 °C; IR (neat, cm-1) 1723 (C=O), 1260 (C-O); 1H NMR δ (500 MHz, 
CDCl3) 4.04 (6H, s, CO2CH3), 2.97-2.95 (4H, m, ArCH2R), 1.86-1.85 (4H, m, 
RCH2R), 1.43-1.38 (4H, m RCH2R); 13C NMR δ (125 MHz, CDCl3) 165.9 (2C, 
ArCO2R), 153.6 (2C, NCRCO2R), 141.6 (2C, R3C), 53.3 (2C, CO2CH3), 30.5 (2C, 
RCH2R), 27.0 (2C, ArCH2R), 26.0 (2C, RCH2R); m/z (ESI+, MeCN) 301.2 ([M+Na]
+, 
58 %), 317.2 ([M+K]+, 6 %); HRMS (ESI+, MeCN) [M+H]+ found 279.1328 
87 
 
(C14H19N2O4 requires 279.1339); HPLC (column 2, method A, ELSD, MeCN) tR 6.00 
min. 
 





Isopentyl nitrite was added to a stirring solution of diester dihydrotetrazine 45 (7.19 
mg, 35.9 µmol, 1 eq) and cycloalkyne 50 (4.08 mg, 37.7 µmol, 1.05 eq) in DCM (0.359 
mL) at rt. The reaction mixture was stirred for 2 h before the solvent was removed 
under reduced pressure to give crude product. The crude product was dissolved in 
deuterated chloroform (~0.75 mL) and a proton NMR spectrum taken immediately. 
Pseudoquantitative proton NMR yields were calculated from the ratio of the CO2CH3 
peaks of diester tetrazine 46 and diester bicyclopyridazine 59 in the proton NMR 
spectrum. 
 
7.4. Chapter 4 Experimental 
 




Oxidant (0.152 mmol, 3 eq) was added to a stirring solution of diester dihydrotetrazine 
45 (10.1 mg, 50.5 µmol, 1 eq) and durene (3.40 mg, 25.3 µmol, 0.5 eq) in DCM-d2 
(0.505 mL) at 25 °C. The reaction mixture was stirred for 2 h before transferring into 
an NMR tube and a proton NMR spectrum taken immediately. qNMR yields were 
calculated from the ArH peak of durene; and the CO2CH3 peaks of diester 
dihydrotetrazine 45 and diester tetrazine 46 in the proton NMR spectrum. 
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Ethyl diazoacetate (2.47 mL, 20.4 mmol, 1 eq) in anhydrous DCM (10 mL) was added 
dropwise to a stirring solution of cis,cis-1,5-cyclooctadiene (COD) (20.0 mL, 0.163 
mol, 8 eq) and rhodium(II) acetate dimer (0.451 g, 1.02 mmol, 5 mol%) in anhydrous 
DCM (10 mL) at rt under nitrogen. The reaction mixture was stirred for 40 h before 
the solvent was removed under reduced pressure to give crude product. The crude 
product was purified by flash column chromatography eluting with hexane up to 
diethyl ether:hexane (1:99) to give (Z)-endo-bicycloalkene ester 65 as a colourless oil 
(1.19 g, 30 %): Rf (Et2O:hexane, 1:99) 0.26; IR (neat, cm
-1) 1720 (C=O), 1152 (C-O); 
1H NMR δ (500 MHz, CDCl3) 5.63-5.57 (2H, m, RCHR), 4.11 (2H, q, J 7.2 Hz, 
CO2CH2R), 2.53-2.47 (2H, m, RCHCH2R), 2.23-2.16 (2H, m, RCH2CHR2), 2.08-2.01 
(2H, m, RCHCH2R), 1.85-1.79 (2H, m, RCH2CHR2), 1.70 (1H, t, J 8.8 Hz, 
R2CHCO2R), 1.42-1.35 (2H, m, R3CH), 1.26 (3H, t, J 7.2 Hz, RCH3); 13C NMR δ 
(125 MHz, CDCl3) 172.4 (1C, RCO2R), 129.5 (2C, RCHR), 59.8 (1C, CO2CH2R), 
27.2 (2C, RCHCH2R), 24.3 (2C, R3CH), 22.8 (2C, RCH2CHR2), 21.3 (1C, 
R2CHCO2R), 14.5 (1C, RCH3); m/z (FAB, MeCN) 195.2 ([M+H]
+, 7 %), 109.1 (31), 
55.0 (100); HPLC (column 2, method A, ELSD, MeCN) tR not observed. The 
spectroscopic data was in agreement with the literature.100 Further elution with diethyl 














(Z)-endo-Bicycloalkene ester 65 (1.00 g, 5.15 mmol, 1 eq) in anhydrous diethyl ether 
(20 mL) was added dropwise to a stirring solution of lithium aluminium hydride (0.176 
g, 4.64 mmol, 0.9 eq) in anhydrous diethyl ether (20 mL) at 0 °C under nitrogen. The 
reaction mixture was warmed to rt and stirred for 30 min before cooling to 0 °C. Water 
was added dropwise to the reaction mixture until the grey solid turned colourless. 
Anhydrous sodium sulfate was added to the reaction mixture and the insoluble solid 
removed by filtration. The filtrand was washed with diethyl ether (100 mL) before the 
solvent removed under reduced pressure to give crude product. The crude product was 
purified by flash column chromatography eluting with hexane up to ethyl 
acetate:hexane (1:4) to give (Z)-endo-bicycloalkene alcohol 66 as a colourless oil 
(0.778 g, 99 %): Rf (EtOAc:hexane, 1:4) 0.14; IR (neat, cm-1) 3325 (O-H), 1673 
(C=C); 1H NMR δ (500 MHz, CDCl3) 5.65-5.59 (2H, m, RCHR), 3.70 (2H, d, J 7.5 
Hz, RCH2OH), 2.38-2.32 (2H, m, RCHCH2R), 2.13-2.06 (2H, m, RCHCH2R), 2.01-
1.94 (2H, m, RCH2CHR2), 1.60-1.53 (2H, m, RCH2CHR2), 1.35 (1H, br s, ROH), 1.15-
1.09 (1H, m, R2CHCH2OH), 1.04-0.96 (2H, m, R3CH); 13C NMR δ (125 MHz, 
CDCl3) 129.9 (2C, RCHR), 60.4 (1C, RCH2OH), 27.8 (2C, RCHCH2R), 24.0 (2C, 
RCH2CHR2), 20.8 (1C, R2CHCH2OH), 19.1 (2C, R3CH); m/z (CI, MeCN) 153.1 
([M+H]+, 52 %), 175.1 ([M+Na]+, 18 %), 191.1 ([M+K]+, 36 %), 167.1 (93), 165.1 
(26), 154.0 (43), 153.1 (52), 152.1 (27), 151.1 (62), 149.1 (98), 147.1 (30), 137.1 (100); 
HRMS (CI, MeCN) [M+H]+ found 153.1269 (C10H17O1 requires 153.1274); HPLC 












Bromine (0.254 mL, 4.95 mmol, 1.1 eq) in DCM (3.5 mL) was added dropwise to a 
stirring solution of (Z)-endo-bicycloalkene alcohol 66 (0.685 g, 4.50 mmol, 1 eq) in 
DCM (35 mL) at 0 °C. The reaction mixture was stirred for 30 min before warming to 
rt and diluting with sodium thiosulfate solution (10 mL, sat aq). The organic layer was 
separated from the aq layer and the aq layer extracted with DCM (3 × 20 mL). The 
organic layer and the combined extracts were dried over anhydrous sodium sulfate 
before the solvent was removed under reduced pressure to give crude product. The 
crude product was purified by flash column chromatography eluting with DCM to give 
(±)-endo,trans-dibromobicycloalkane alcohol 67 as a colourless solid (1.00 g, 71 %): 
Rf (DCM) 0.28; mp 116-118 °C; IR (neat, cm-1) 3187 (O-H), 701 (C-Br); 1H NMR δ 
(500 MHz, CDCl3) 4.82-4.78 (2H, m, RCHBrR), 3.79-3.71 (2H, m, RCH2OH), 2.73-
2.62 (2H, m, RCHBrCH2R), 2.30-2.23 (1H, m, RCHBrCH2R), 2.18-2.12 (1H, m, 
RCHBrCH2R), 1.97-1.86 (2H, m, RCH2CHR2), 1.67-1.53 (2H, m, RCH2CHR2), 1.38 
(1H, br s, ROH), 1.24-1.05 (3H, m, R2CHCH2OH and R3CH); 13C NMR δ (125 MHz, 
CDCl3) 59.7 (1C, RCH2OH), 56.3 (1C, RCHBrR), 53.4 (1C, RCHBrR), 35.1 (2C, 
RCHBrCH2R), 22.0 (1C, R2CHCH2OH), 20.2 (1C, R3CH), 20.0 (1C, RCH2CHR2), 
19.1 (1C, RCH2CHR2), 17.3 (1C, R3CH); m/z (CI, MeCN) 310.9 ([M+H]
+, 23 %), 
333.2 ([M+Na]+, 4 %), 319.2 (33), 297.9 (100); HRMS (CI, MeCN) [M+H]+ found 
310.9636 (Br2C10H17O1 requires 310.9641); HPLC (column 2, method A, ELSD, 










1 M Potassium tert-butoxide solution in anhydrous THF (10.6 mL, 10.6 mmol, 3.3 eq) 
was added dropwise to a stirring solution of (±)-endo,trans-dibromobicycloalkane 
alcohol 67 (1.00 g, 3.20 mmol, 1 eq) in anhydrous THF (35 mL) at 0 °C under nitrogen. 
The reaction mixture was heated to reflux and stirred for 2 h before cooling to rt and 
diluting with ammonium chloride solution (30 mL, sat aq). The aq layer was extracted 
with DCM (3 × 30 mL). The combined organic extracts were washed with water (1 × 
30 mL) and sodium chloride solution (1 × 30 mL, sat aq) then dried over anhydrous 
sodium sulfate before the solvent was removed under reduced pressure to give crude 
product. The crude product was purified by flash column chromatography eluting with 
hexane up to ethyl acetate:hexane (3:17) to give endo-BCN-OH 60 as a colourless 
solid (0.175 g, 36 %): Rf (EtOAc:hexane, 3:17) 0.26; mp 58-60 °C; IR (neat, cm-1) 
3304 (O-H), 2184 (C≡C); 1H NMR δ (500 MHz, CDCl3) 3.71 (2H, d, J 8.0 Hz, 
RCH2OH), 2.31-2.18 (6H, m, RCH2CHR2 and RCCH2R), 1.62-1.55 (2H, m, 
RCH2CHR2), 1.44 (1H, br s, ROH), 1.35-1.29 (1H, m, R2CHCH2OH), 0.94-0.90 (2H, 
m, R3CH); 13C NMR δ (125 MHz, CDCl3) 99.0 (2C, RCR), 60.0 (1C, RCH2OH), 29.2 
(2C, RCH2CHR2), 21.6 (2C, RCCH2R), 21.5 (1C, R2CHCH2OH), 20.1 (2C, R3CH); 
m/z (EI, MeCN) 150.1 ([M]+., 13 %), 149.0 (100), 135.1 (61), 131.1 (68); HPLC 
(column 2, method A, ELSD, MeCN) tR not observed. The spectroscopic data was in 













Ethyl diazoacetate (2.47 mL, 20.4 mmol, 1 eq) in anhydrous DCM (10 mL) was added 
dropwise to a stirring solution of COD (20.0 mL, 0.163 mol, 8 eq) and rhodium(II) 
acetate dimer (0.451 g, 1.02 mmol, 5 mol%) in anhydrous DCM (10 mL) at rt under 
nitrogen. The reaction mixture was stirred for 40 h before the solvent was removed 
under reduced pressure to give crude product. The crude product was purified by flash 
column chromatography eluting with hexane up to diethyl ether:hexane (1:99) to give 
(Z)-endo-bicycloalkene ester 65 as a colourless oil (1.19 g, 30 %). Further elution with 
diethyl ether:hexane (1:99) gave (Z)-exo-bicycloalkene ester 65 as a colourless oil 
(1.87 g, 47 %): Rf (Et2O:hexane, 1:99) 0.23; IR (neat, cm
-1) 1719 (C=O), 1154 (C-O); 
1H NMR δ (500 MHz, CDCl3) 5.66-5.60 (2H, m, RCHR), 4.10 (2H, q, J 7.0 Hz, 
CO2CH2R), 2.33-2.27 (2H, m, RCHCH2R), 2.22-2.16 (2H, m, RCH2CHR2), 2.11-2.05 
(2H, m, RCHCH2R), 1.59-1.53 (2H, m, R3CH), 1.51-1.44 (2H, m, RCH2CHR2), 1.25 
(3H, t, J 7.0 Hz, RCH3), 1.18 (1H, t, J 4.5 Hz, R2CHCO2R); 13C NMR δ (125 MHz, 
CDCl3) 174.6 (1C, RCO2R), 130.1 (2C, RCHR), 60.4 (1C, CO2CH2R), 28.4 (2C, 
RCH2CHR2), 28.0 (1C, R2CHCO2R), 27.9 (2C, R3CH), 26.8 (2C, RCHCH2R), 14.4 
(1C, RCH3); m/z (FAB, MeCN) 195.1 ([M+H]
+, 12 %), 149.1 (36), 121.1 (93), 107.1 
(33), 57.1 (100); HPLC (column 2, method A, ELSD, MeCN) tR not observed. The 







(Z)-exo-Bicycloalkene ester 65 (1.65 g, 8.49 mmol, 1 eq) in anhydrous diethyl ether 
(33 mL) was added dropwise to a stirring solution of lithium aluminium hydride (0.290 
g, 7.64 mmol, 0.9 eq) in anhydrous diethyl ether (33 mL) at 0 °C under nitrogen. The 
reaction mixture was warmed to rt and stirred for 30 min before cooling to 0 °C. Water 
was added dropwise to the reaction mixture until the grey solid turned colourless. 
Anhydrous sodium sulfate was added to the reaction mixture and the insoluble solid 
removed by filtration. The filtrand was washed with diethyl ether (150 mL) before the 
solvent removed under reduced pressure to give crude product. The crude product was 
purified by flash column chromatography eluting with hexane up to ethyl 
acetate:hexane (1:4) to give (Z)-exo-bicycloalkene alcohol 66 as a colourless oil (1.10 
g, 85 %): Rf (EtOAc:hexane 1:4) 0.13; IR (neat, cm-1) 3317 (O-H); 1H NMR δ (500 
MHz, CDCl3) 5.66-5.60 (2H, m, RCHR), 3.48-3.46 (2H, d, J 7.0 Hz, RCH2OH), 2.32-
2.26 (2H, m, RCHCH2R), 2.20-2.13 (2H, m, RCH2CHR2), 2.10-2.03 (2H, m, 
RCHCH2R), 1.44-1.37 (3H, m, RCH2CHR2 and ROH), 0.81-0.74 (2H, m, R3CH), 
0.68-0.63 (1H, m, R2CHCH2OH); 13C NMR δ (125 MHz, CDCl3) 130.3 (2C, RCHR), 
67.4 (1C, RCH2OH), 29.2 (2C, RCH2CHR2), 29.0 (1C, R2CHCH2OH), 27.2 (2C, 
RCHCH2R), 22.2 (2C, R3CH); m/z (CI, MeCN) 153.1 ([M+H]
+, 13 %), 152.1 (62), 
151.1 (100); HPLC (column 2, method A, ELSD, MeCN) tR not observed. The 







Bromine (0.374 mL, 7.23 mmol, 1.1 eq) in DCM (5 mL) was added dropwise to a 
stirring solution of (Z)-exo-bicycloalkene alcohol 66 (1.00 g, 6.57 mmol, 1 eq) in DCM 
(50 mL) at 0 °C. The reaction mixture was stirred for 30 min before warming to rt and 
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diluting with sodium thiosulfate solution (10 mL, sat aq). The organic layer was 
separated from the aq layer and the aq layer extracted with DCM (3 × 20 mL). The 
organic layer and the combined extracts were dried over anhydrous sodium sulfate 
before the solvent was removed under reduced pressure to give crude product. The 
crude product was purified by flash column chromatography eluting with DCM to give 
(±)-exo,trans-dibromobicycloalkane alcohol 67 as a colourless solid (1.74 g, 85 %): 
Rf (DCM) 0.16; mp 49-51 °C; IR (neat, cm-1) 3261 (O-H), 1024 (C-O), 699 (C-Br); 
1H NMR δ (400 MHz, CDCl3) 4.84-4.77 (2H, m, RCHBrR), 3.49 (2H, d, J 12.0 Hz, 
RCH2OH), 2.69-2.55 (2H, m, RCHBrCH2R), 2.28-2.19 (1H, m, RCHBrCH2R), 2.10-
2.03 (3H, m, RCHBrCH2R and RCH2CHR2), 1.71 (1H, s, ROH), 1.48-1.30 (2H, m, 
RCH2CHR2), 0.94-0.80 (2H, m, R3CH), 0.68-0.62 (1H, m, R2CHCH2OH); 13C NMR 
δ (100 MHz, CDCl3) 66.6 (1C, RCH2OH), 56.3 (1C, RCHBrR), 53.4 (1C, RCHBrR), 
35.0 (1C, RCHBrCH2R), 34.9 (1C, RCHBrCH2R), 28.2 (1C, R2CHCH2OH), 24.5 (1C, 
RCH2CHR2), 23.7 (1C, RCH2CHR2), 22.6 (1C, R3CH), 19.9 (1C, R3CH); m/z (CI, 
MeCN) 310.9 ([M+H]+, 100 %), 308.9 (56); HRMS (CI, MeCN) [M+H]+ found 
310.9469 (Br2C10H17O1 requires 310.9641); HPLC (column 2, method A, ELSD, 






1 M Potassium tert-butoxide solution in anhydrous THF (16.6 mL, 16.6 mmol, 3.3 eq) 
was added dropwise to a stirring solution of (±)-exo,trans-dibromobicycloalkane 
alcohol 67 (1.57 g, 5.03 mmol, 1 eq) in anhydrous THF (55 mL) at 0 °C under nitrogen. 
The reaction mixture was heated to reflux and stirred for 2 h before cooling to rt and 
diluting with ammonium chloride solution (50 mL, sat aq). The aq layer was extracted 
with DCM (3 × 50 mL). The combined organic extracts were washed with water (1 × 
50 mL) and sodium chloride solution (1 × 50 mL, sat aq) then dried over anhydrous 
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sodium sulfate before the solvent was removed under reduced pressure to give crude 
product. The crude product was purified by flash column chromatography eluting with 
hexane up to ethyl acetate:hexane (3:17) to give exo-BCN-OH 60 as a colourless solid 
(0.246 g, 33 %): Rf (EtOAc:hexane, 3:17) 0.16; mp 60-61 °C; IR (neat, cm-1) 3264 
(O-H); 1H NMR δ (500 MHz, CDCl3) 3.55 (2H, d, J 6.2 Hz, RCH2OH), 2.43-2.40 
(2H, m, RCH2CHR2), 2.31-2.26 (2H, m, RCCH2R), 2.17-2.14 (2H, m, RCCH2R), 
1.42-1.35 (2H, m, RCH2CHR2), 0.73-0.64 (3H, m, R3CH and R2CHCH2OH); 13C 
NMR δ (125 MHz, CDCl3) 99.0 (2C, RCR), 67.3 (1C, RCH2OH), 33.6 (2C, 
RCH2CHR2), 27.5 (1C, R2CHCH2OH), 22.7 (2C, R3CH), 21.6 (2C, RCCH2R); m/z 
(CI, MeCN) 151.1 ([M+H]+, 24 %), 135.1 (25), 42.4 (100); HPLC (column 2, method 







mCPBA (50.0 g, 0.203 mol, 1 eq) in chloroform (460 mL) was added dropwise to a 
stirring solution of COD (22.0 g, 0.203 mol, 1 eq) at rt. The reaction mixture was 
stirred overnight before the insoluble solid was removed by filtration. The filtrate was 
washed with sodium bisulfate solution (1 × 450 mL, sat aq), sodium bicarbonate 
solution (1 × 450 mL, sat aq) and sodium chloride solution (1 × 450 mL, sat aq) then 
dried over anhydrous magnesium sulfate before the solvent was removed under 
reduced pressure to give crude product. The crude product was purified by flash 
column chromatography eluting with ethyl acetate:hexane (1:19) to give (Z)-
cycloalkene epoxide 68 as a colourless oil (14.0 g, 56 %): Rf (EtOAc:hexane, 1:19) 
0.25; IR (neat, cm-1) 1656 (C=C); 1H NMR δ (500 MHz, CDCl3) 5.60-5.52 (2H, m, 
RCHR), 3.05-3.01 (2H, m, RCHOR), 2.47-2.41 (2H, m, RCHCH2R), 2.17-2.09 (2H, 
m, RCH2CHOR), 2.07-1.98 (4H, m, RCHCH2R and RCH2CHOR); 13C NMR δ (125 
MHz, CDCl3) 129.0 (2C, RCHR), 56.8 (2C, RCHOR), 28.2 (2C, RCH2CHOR), 23.8 
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(2C, RCHCH2R); m/z (CI, MeCN) 125.1 ([M+H]
+, 12 %), 124.1 (36), 108.1 (26), 
107.1 (100); HPLC (column 2, method A, ELSD, MeCN) tR not observed. The 






1 M Lithium aluminium hydride solution in anhydrous THF (53.5 mL, 53.5 mmol, 0.5 
eq) was added dropwise to a stirring solution of (Z)-cycloalkene epoxide 68 (13.3 g, 
0.107 mol, 1 eq) in anhydrous THF at rt under nitrogen. The reaction mixture was 
stirred overnight before cooling to 0 °C and diluting with water (50 mL). The insoluble 
solid was removed by filtration and washed with diethyl ether (3 × 20 mL) before the 
solvent was removed under reduced pressure to give crude product. The crude product 
was purified by flash column chromatography eluting with hexane up to ethyl 
acetate:hexane (3:7) to give (±)-(Z)-cycloalkene alcohol 61 as a colourless oil (9.78 g, 
72 %): Rf (EtOAc:hexane, 3:7) 0.35; IR (neat, cm-1) 3332 (O-H); 1H NMR δ (500 
MHz, CDCl3) 5.71-5.65 (1H, m, RCHR), 5.60-5.55 (1H, m, RCHR), 3.81-3.77 (1H, 
m, RCHOHR), 2.32-2.24 (1H, m, RCHCH2R), 2.15-2.06 (3H, m, RCHCH2R), 1.94-
1.87 (1H, m, RCH2CHOHR), 1.86-1.80 (1H, m, RCH2CHOHR), 1.73-1.68 (1H, m, 
RCH2CHOHR), 1.66-1.59 (2H, m, RCH2R and ROH), 1.56-1.46 (2H, m, 
RCH2CHOHR and RCH2R); 13C NMR δ (125 MHz, CDCl3) 130.3 (1C, RCHR), 129.7 
(1C, RCHR), 72.8 (1C, RCHOHR), 37.8 (1C, RCH2CHOHR), 36.4 (1C, 
RCH2CHOHR), 25.8 (1C, RCHCH2R), 25.0 (1C, RCH2R), 22.9 (1C, RCHCH2R); m/z 
(EI, MeCN) 126.1 ([M]+., 8 %), 108.1 (32), 98.1 (100), 67.1 (100); HPLC (column 2, 
method A, ELSD, MeCN) tR not observed. The spectroscopic data was in agreement 










Propionyl chloride (1.59 mL, 18.2 mmol, 1 eq) and triethylamine (3.04 mL, 21.8 
mmol, 1.2 eq) were added to a stirring solution of allylamine (1.37 mL, 18.2 mmol, 1 
eq) in DCM at 0 °C. The reaction mixture was warmed to rt and stirred for 2 h before 
diluting with hydrochloric acid (100 mL, 1 M aq). The organic layer was separated 
from the aq layer and the aq layer extracted with chloroform (3 × 50 mL). The organic 
layer and combined organic extracts were dried over magnesium sulfate before the 
solvent was removed under reduced pressure to give crude product. The crude product 
was purified by flash column chromatography eluting with ethyl acetate:hexane (1:1) 
to give allyl amide 62 as a yellow oil (1.92 g, 93 %): Rf (EtOAc:hexane, 1:1) 0.32; IR 
(neat, cm-1) 1643 (C=O), 1546 (N-H); 1H NMR δ (400 MHz, CDCl3) 5.83 (1H, ddt, J 
17.2, 10.4 and 5.6 Hz, H2CCHR), 5.60 (1H, br s, RNHCOR), 5.17 (1H, dq, J 17.2 and 
1.6 Hz, H2CCHR), 5.12 (1H, dq, J 10.4 and 1.6 Hz, H2CCHR), 3.88 (2H, tt, J 5.6 and 
1.6 Hz, H2CCHCH2R), 2.23 (2H, q, J 7.6 Hz, NHCOCH2R), 1.16 (3H, t, J 7.6 Hz, 
RCH3); 13C NMR δ (125 MHz, CDCl3) 173.7 (1C, RNHCOR), 134.4 (1C, H2CCHR), 
116.5 (1C, H2CCHR), 42.0 (1C, H2CCHCH2R), 29.8 (1C, NHCOCH2R), 10.0 (1C, 
RCH3); m/z (ESI+, MeCN) 114.3 ([M+H]
+, 76 %), 136.2 ([M+Na]+, 6 %), 227.3 
([2M+H]+, 100 %), 249.2 ([2M+Na]+, 13 %); HRMS (EI, MeCN) [M]+. found 
113.0833 (C6H11NO requires 113.0835); HPLC (column 1, method A, ELSD, MeCN) 
tR not observed. The spectroscopic data was in agreement with the literature.
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Dienophile (53.0 µmol, 1.05 eq) was added to a stirring solution of diester tetrazine 46 
(10.0 mg, 50.5 µmol, 1 eq) and durene (3.40 mg, 25.3 µmol, 0.5 eq) in DCM-d2 (0.505 
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mL) at 25 °C. The reaction mixture was stirred for 2 h before transferring to an NMR 
tube and a proton NMR spectrum taken immediately. The qNMR yield was calculated 
from the ArH peak of durene and a characteristic peak of diester (dihydro)pyridazine 







endo-BCN-OH 60 (49.3 mg, 0.328 mmol, 1.05 eq) was added slowly to a stirring 
solution of diester tetrazine 46 (61.8 mg, 0.312 mmol, 1 eq) in DCM (3.12 mL) at 25 
°C. The reaction mixture was stirred for 2 h before the solvent was removed under 
reduced pressure to give crude product. The crude product was purified by automated 
flash column chromatography eluting with DCM to give endo-diester 
tricyclopyridazine alcohol 70 as a colourless solid (85.0 mg, 85 %): Rf (DCM:MeOH, 
39:1) 0.32; mp 124-126 °C; IR (neat, cm-1) 3411 (O-H), 1730 (C=O), 1147 (C-O); 1H 
NMR δ (400 MHz, CDCl3) 4.03 (6H, s, CO2CH3), 3.70 (2H, d, J 7.7 Hz, RCH2OH), 
3.08-2.94 (4H, m, ArCH2R), 2.44-2.39 (2H, m, RCH2CHR2), 1.65-1.53 (3H, m, 
RCH2CHR2 and ROH), 1.17-1.08 (1H, m, R2CHCH2OH), 0.97-0.87 (2H, m, R3CH); 
13C NMR δ (100 MHz, CDCl3) 166.0 (2C, ArCO2R), 154.2 (2C, NCRCO2R), 143.3 
(2C, R3C), 59.4 (1C, RCH2OH), 53.4 (2C, CO2CH3), 27.7 (2C, ArCH2R), 23.6 (2C, 
RCH2CHR2), 22.4 (1C, R2CHCH2OH), 18.8 (2C, R3CH); m/z (ESI+, MeCN) 321.0 
([M+H]+, 14 %), 662.9 ([2M+Na]+, 30 %), 146.0 (100), 105.2 (64); HRMS (ESI+, 
MeCN) [M+H]+ found 321.1452 (C16H21N2O5 requires 321.1445); HPLC (column 2, 









exo-BCN-OH 60 (49.3 mg, 0.328 mmol, 1.05 eq) was added slowly to a stirring 
solution of diester tetrazine 46 (61.8 mg, 0.312 mmol, 1 eq) in DCM (3.12 mL) at 25 
°C. The reaction mixture was stirred for 2 h before the solvent was removed under 
reduced pressure to give crude product. The crude product was purified by automated 
flash column chromatography eluting with DCM up to DCM:methanol (39:1) to give 
exo-diester tricyclopyridazine alcohol 70 as a colourless solid (89.0 mg, 89 %): Rf 
(DCM:MeOH, 39:1) 0.29; mp 107-109 °C; IR (neat, cm-1) 3414 (O-H), 1728 (C=O), 
1160 (C-O); 1H NMR δ (400 MHz, CDCl3) 4.01 (6H, s, CO2CH3), 3.34 (2H, d, J 6.8 
Hz, RCH2OH), 3.03-2.89 (4H, m, ArCH2R), 2.63-2.54 (2H, m, RCH2CHR2), 1.80 (1H, 
br s, ROH), 1.48-1.39 (2H, m, RCH2CHR2), 0.80-0.74 (1H, m, R2CHCH2OH), 0.68-
0.60 (2H, m, R3CH); 13C NMR δ (100 MHz, CDCl3) 165.9 (2C, ArCO2R), 154.1 (2C, 
NCRCO2R), 142.5 (2C, R3C), 65.9 (1C, RCH2OH), 53.3 (2C, CO2CH3), 30.4 (1C, 
R2CHCH2OH), 28.5 (2C, RCH2CHR2), 27.4 (2C, ArCH2R), 20.8 (2C, R3CH); m/z 
(ESI+, MeCN) 321.0 ([M+H]+, 18 %), 342.9 ([M+Na]+, 6 %), 662.9 ([2M+Na]+, 51 
%), 146.1 (100), 105.2 (70); HRMS (ESI+, MeCN) [M+H]+ found 321.1446 














Allyl propionate (46.2 µl, 0.370 mmol, 1.05 eq) was added slowly to a stirring solution 
of diester tetrazine 46 (69.7 mg, 0.352 mmol, 1 eq) in DCM (3.52 mL) at 25 °C. The 
reaction mixture was stirred for 2 h before the solvent was removed under reduced 
pressure to give crude product. The crude product was purified by flash column 
chromatography eluting with DCM to give diester dihydropyridazine ester 73 as a 
colourless gum (84.0 mg, 84 %): Rf (DCM:MeOH, 99:1) 0.24; IR (neat, cm-1) 3352 
(N-H), 1726 (C=O), 1173 (C-O), 1122 (C-O); 1H NMR δ (500 MHz, CDCl3) 8.33 
(1H, br s, RNHN), 5.84-5.83 (1H, m, RCHR), 4.15 (1H, dd, J 10.8 and 5.0 Hz, 
RCH2OCOR), 4.03-4.00 (1H, m, R3CH), 3.94 (1H, dd, J 10.8 and 5.0 Hz, 
RCH2OCOR), 3.87 (3H, s, CO2CH3), 3.86 (3H, s, CO2CH3), 2.29 (2H, q, J 7.6 Hz, 
OCOCH2R), 1.10 (3H, t, J 7.6 Hz, RCH3); 13C NMR δ (125 MHz, CDCl3) 174.3 (1C, 
ROCOR), 164.6 (1C, RCO2R), 161.5 (1C, RCO2R), 130.7 (1C, NCRCO2R), 130.6 
(1C, RCNHCO2R), 106.4 (1C, RCHR), 64.5 (1C, RCH2OCOR), 52.9 (1C, CO2CH3), 
52.8 (1C, CO2CH3), 32.2 (1C, R3CH), 27.6 (1C, OCOCH2R), 9.1 (1C, RCH3); m/z 
(ESI+, MeCN) 285.0 ([M+H]+, 5 %), 307.0 ([M+Na]+, 45 %), 322.9 ([M+K]+, 10 %), 
590.8 ([2M+Na]+, 100 %), 146.0 (83), 105.2 (69); HRMS (ESI+, MeCN) [M+Na]+ 
found 307.0910 (C12H16N2NaO6 requires 307.0901); HPLC (column 2, method A, 












Oxidant (0.152 mmol, 3 eq) was added to a stirring solution of diester dihydrotetrazine 
45 (10.1 mg, 50.5 µmol, 1 eq), durene (3.40 mg, 25.3 µmol, 0.5 eq) and dienophile 
(53.0 µmol, 1.05 eq) in DCM-d2 (0.505 mL) at 25 °C. The reaction mixture was stirred 
for 2 h before transferring to an NMR tube and a proton NMR spectrum taken 
immediately. qNMR yields were calculated from the ArH peak of durene; and the 
CO2CH3 peaks of diester tetrazine 46 and diester pyridazine in the proton NMR 
spectrum. 
 




DDQ (0.241 g, 1.06 mmol, 3 eq) was added to a stirring solution of diester 
dihydrotetrazine 45 (70.9 mg, 0.354 mmol, 1 eq) and allyl propionate (46.5 µl, 0.372 
mmol, 1.05 eq) in DCM at 25 °C. The reaction mixture was stirred for 2 h before the 
insoluble solid was removed by filtration and the solvent removed under reduced 
pressure to give crude product. The crude product was purified by flash column 
chromatography eluting with DCM to give diester pyridazine ester 74 as a yellow oil 
(97.4 mg, 97 %): Rf (DCM:MeOH, 99:1) 0.14; IR (neat, cm-1) 1729 (C=O), 1263 (C-
O), 1137 (C-O); 1H NMR δ (500 MHz, CDCl3) 8.31 (1H, s, ArH), 5.55 (2H, s, 
ArCH2OCOR), 4.11 (3H, s, CO2CH3), 4.09 (3H, s, CO2CH3), 2.52 (2H, q, J 7.6 Hz, 
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OCOCH2R), 1.23 (3H, t, J 7.6 Hz, RCH3); 13C NMR δ (125 MHz, CDCl3) 173.6 (1C, 
ROCOR), 164.6 (1C, ArCO2R), 164.1 (1C, ArCO2R), 152.4 (1C, Ar), 150.6 (1C, Ar), 
139.8 (1C, Ar), 125.9 (1C, ArH), 61.2 (1C, ArCH2OCOR), 53.8 (2C, CO2CH3), 27.5 
(1C, OCOCH2R), 9.2 (1C, RCH3); m/z (ESI+, MeCN) 283.0 ([M+H]
+, 14 %), 304.8 
([M+Na]+, 8 %), 586.8 ([2M+Na]+, 100 %), 130.3 (72); HRMS (ESI+, MeCN) 
[M+Na]+ found 305.0745 (C12H14N2NaO6 requires 305.0744); HPLC (column 2, 
method A, MeCN, ELSD) tR 5.15 min. 
 
7.5. Chapter 5 Experimental 
 




Aminomethyl polystyrene resin (25.0 mg, 0.745 mmolg-1) was functionalised 
according to general procedure 1 then Fmoc deprotected and amino acid coupled with 
Fmoc-Aaa-OH (Table 6) according to general procedure 2. DDQ (12.7 mg, 55.8 µmol, 
3 eq) was added to the resin in DCM (0.186 mL) at rt. The resin was agitated for 4 h 
then filtered before washing with DMF (× 3), DCM (× 3), methanol (× 3) and diethyl 
ether (× 3). The linker was cleaved according to general procedure 3 to give Fmoc-











Entry Fmoc-Aaa-OH Fmoc-Aaa-NH2 
79 
HPLCa m/zb 
tR/min Purity/% [M+H]+ 
I Fmoc-Arg(Pbf)-OH Fmoc-Arg-NH2 5.29 100 396.0 (100) 
II Fmoc-Asn(Trt)-OH Fmoc-Asn-NH2 6.05 100 354.0 (45) 
III Fmoc-Asp(OtBu)-OH Fmoc-Asp-NH2 6.38 100 355.0 (70) 
IV Fmoc-Cys(Trt)-OH Fmoc-Cys-NH2 7.30 100 343.0 (10) 
V Fmoc-Gln(Trt)-OH Fmoc-Gln-NH2 6.04 100 368.0 (75) 
VI Fmoc-Glu(OtBu)-OH Fmoc-Glu-NH2 6.37 100 368.9 (49) 
VII Fmoc-His(Trt)-OH Fmoc-His-NH2 4.96 100 377.0 (100) 
VIII Fmoc-Lys(Boc)-OH Fmoc-Lys-NH2 4.96 100 368.2 (100) 
IX Fmoc-Met-OH Fmoc-Met-NH2 6.13 96 370.9 (7) 
X Fmoc-Ser(tBu)-OH Fmoc-Ser-NH2 6.22 100 327.0 (24) 
XI Fmoc-Thr(tBu)-OH Fmoc-Thr-NH2 6.48 100 341.0 (53) 
XII Fmoc-Trp(Boc)-OH Fmoc-Trp-NH2 7.83 100 425.9 (31) 
XIII Fmoc-Tyr(tBu)-OH Fmoc-Tyr-NH2 6.93 100 403.0 (70) 
 
Table 6. Investigation into the stability of resin-bound amino acids towards DDQ. a Column 2, method 







DSC (0.256 g, 0.999 mmol, 1.5 eq) was added to a stirring solution of endo-BCN-OH 
60 (0.100 g, 0.666 mmol, 1 eq) and triethylamine (0.371 mL, 2.66 mmol, 4 eq) in 
anhydrous acetonitrile at 0 °C under nitrogen. The reaction mixture was warmed to rt 
and stirred for four h before the solvent was removed under reduced pressure to give 
crude product. The crude product was purified by flash column chromatography 
eluting with hexane up to ethyl acetate:hexane (2:3) to give endo-BCN-OSu 80 as a 
colourless solid (0.139 g, 72 %): Rf (EtOAc:hexane, 2:3) 0.36; mp 119-121 °C; IR 
(neat, cm-1) 1808 (C=O), 1788 (C=O), 1731 (C=O), 1212 (C-O), 1204 (C-O); 1H NMR 
δ (500 MHz, CDCl3) 4.45 (2H, d, J 8.4 Hz, RCH2OCO2R), 2.83 (4H, s, R2NCOCH2R), 
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2.34-2.21 (6H, m, RCCH2R and RCH2CHR2), 1.62-1.46 (3H, m, RCCH2R and 
R2CHCH2OCO2R), 1.09-1.02 (2H, m, R3CH); 13C NMR δ (125 MHz, CDCl3) 168.8 
(2C, RCONR2), 151.8 (1C, ROCO2R), 98.8 (2C, RCR), 70.5 (1C, RCH2OCO2R), 29.1 
(2C, RCCH2R), 25.6 (2C, R2NCOCH2R), 21.5 (2C, R3CH), 20.9 (2C, RCH2CHR2), 
17.3 (1C, R2CHCH2OCO2R); m/z (CI, MeCN) 292.3 ([M+H]
+, 27 %), 291.2 (100), 
290.2 (81), 120.1 (100); HRMS (CI, MeCN) [M+H]+ found 292.1181 (C15H18NO5 
requires 292.1180); HPLC (column 2, method A, ELSD, MeCN) tR 7.99 min. 
 
(2S)-6-({[(1R,8S,9S)-Bicyclo[6.1.0]non-4-yn-9-ylmethoxy]carbonyl} 




endo-BCN-OSu 80 (0.200 g, 0.687 mmol, 1 eq) in anhydrous DMF (0.60 mL) was 
added to a stirring solution of Fmoc-Lys-OH hydrochloride (0.417 g, 1.03 mmol, 1.5 
eq) and DIPEA (0.239 mL, 1.37 mmol, 2 eq) in anhydrous DMF (1.80 mL) at rt under 
nitrogen. The reaction mixture was stirred overnight before diluting with diethyl ether 
(20 mL). The reaction mixture was washed with water (3 × 20 mL) then dried over 
anhydrous magnesium sulfate before the solvent was removed under reduced pressure 
to give crude product. The crude product was purified by flash column 
chromatography eluting with DCM up to DCM:methanol (2:23) to give Fmoc-
Lys(endo-BCN)-OH 75 as a colourless solid (0.200 g, 53 %): Rf (DCM:MeOH, 9:1) 
105 
 
0.33; mp 178-179 °C; IR (neat, cm-1) 3314 (O-H), 1694 (C=O), 1242 (C-O); 1H NMR 
δ (500 MHz, DMSO-d6) 7.87 (2H, d, J 7.5 Hz, ArH), 7.70 (2H, d, J 6.0 Hz, ArH), 7.40 
(2H, t, J 7.5 Hz, ArH), 7.32 (2H, t, J 7.5 Hz, ArH), 7.04 (2H, br s, ROCONHR), 4.30-
4.21 (3H, m, R3CH and RCH2OCONHR), 3.99 (2H, d, J 7.7 Hz, RCH2OCONHR), 
3.84 (1H, br s, ROCONHCHRCO2H), 2.94 (2H, br s, ROCONHCH2R), 2.22-2.10 
(5H, m, RCCH2R and RCH2R), 1.71-1.21 (10H, m, RCH2CHR2, R2CHCH2OCONHR 
and RCH2R), 0.83-0.80 (2H, m, R3CH); 13C NMR δ (125 MHz, DMSO-d6) 175.6 (1C, 
ROCONHR), 156.4 (1C, RCO2H), 155.7 (1C, ROCONHR), 144.0 (1C, Ar), 143.8 
(1C, Ar), 140.7 (2C, Ar), 127.6 (2C, ArH), 127.0 (2C, ArH), 125.3 (1C, ArH), 125.2 
(1C, ArH), 120.1 (2C, ArH), 99.0 (2C, RCR), 65.4 (1C, RCH2OCONHR), 61.2 (1C, 
RCH2OCONHR), 54.9 (1C, ROCONHCHRCO2H), 46.8 (1C, R3CH), 40.2 (1C, 
ROCONHCH2R), 31.7 (1C, RCH2R), 29.3 (2C, RCH2CHR2), 28.6 (1C, RCH2R), 22.7 
(1C, RCH2R), 20.8 (2C, RCCH2R), 19.5 (2C, R3CH), 17.7 (1C, R2CHCH2OCONHR); 
m/z (ESI+, MeCN) 567.2 ([M+Na]+, 25 %), 324.2 (27), 146.1 (50), 115.2 (30), 105.2 
(52), 102.3 (100); HRMS (ESI+, MeCN) [M+Na]+ found 567.2481 (C32H36N2O6Na 

























Aminomethyl polystyrene resin (80.0 mg, 0.745 mmolg-1) was functionalised 
according to general procedure 1 then Fmoc deprotected and amino acid coupled with 
Fmoc-Lys(endo-BCN)-OH 75 according to general procedure 2. The resin (1 eq) was 
swollen in DCM for 5 min then washed with DCM (× 3). Diester dihydrotetrazine 45 
(12.5 mg, 62.5 µmol, 1.05 eq) in DCM (0.595 mL) and DDQ (40.6 mg, 0.179 mmol, 
3 eq) were added to the resin at rt. The resin was agitated for 4 h then filtered before 
washing with DMF (× 3), DCM (× 3), methanol (× 3) and diethyl ether (× 3). The 
linker was cleaved according to general procedure 3 to give crude product. The crude 
product was purified by flash column chromatography eluting with DCM up to 
DCM:methanol (49:1) to give endo-diester tricyclopyridazine derivatised Fmoc-Lys-
NH2 82 as a colourless solid (37.0 mg, 87 %): Rf (DCM:MeOH, 19:1) 0.40; mp 178-
179 °C; IR (neat, cm-1) 3318 (N-H), 1682 (C=O), 1260 (C-O), 1156 (C-O); 1H NMR 
δ (500 MHz, CDCl3) 7.74 (2H, d, J 7.5 Hz, ArH), 7.57 (2H, m, ArH), 7.38 (2H, t, J 
7.4 Hz, ArH), 7.29 (2H, t, J 7.5 Hz, ArH), 6.26 (1H, br s, RCONH2), 5.73-5.69 (2H, 
m, ROCONHR and RCONH2), 4.86 (1H, br s, ROCONHR), 4.44-4.35 (2H, m, 
107 
 
RCH2OCONHR), 4.20-4.17 (2H, m, R3CH and ROCONHCHRCNH2), 4.14-4.06 (2H, 
m, RCH2OCONHR), 4.02 (6H, s, CO2CH3), 3.19-3.12 (2H, m, ROCONHCH2R), 
3.02-2.92 (4H, m, ArCH2R), 2.34 (2H, br s, RCH2CHR2), 1.86 (1H, br s, RCH2R), 
1.67-1.51 (5H, m, RCH2R), 1.39 (2H, m, RCH2R), 1.10-1.07 (1H, m, 
R2CHCH2OCONHR), 0.84 (2H, br s, R3CH); 13C NMR δ (125 MHz, CDCl3) 174.3 
(1C, ROCONHR), 166.0 (2C, ArCO2R), 157.0 (1C, RCONH2), 156.5 (1C, 
ROCONHR), 154.2 (2C, Ar), 143.8 (2C, Ar), 142.3 (2C, Ar), 141.4 (2C, Ar), 127.9 
(2C, ArH), 127.2 (2C, ArH), 125.2 (1C, ArH), 125.1 (1C, ArH), 120.1 (2C, ArH), 67.1 
(1C, RCH2OCONHR), 62.2 (1C, RCH2OCONHR), 54.4 (1C, 
ROCONHCHRCONH2), 53.4 (2C, CO2CH3), 47.3 (1C, R3CH), 40.3 (1C, 
ROCONHCH2R), 31.8 (1C, RCH2R), 29.5 (1C, RCH2R), 27.5 (2C, ArCH2R), 23.3 
(2C, RCH2CHR2), 22.4 (1C, RCH2R), 18.8 (1C, R2CHCH2OCONHR), 18.5 (2C, 
R3CH); m/z (ESI+, MeCN) 714.2 ([M+H]
+, 29 %), 736.2 ([M+Na]+, 7 %), 317.3 (56), 
102.3 (100); HRMS (ESI+, MeCN) [M+H]+ found 714.3137 (C38H44N5O9 requires 








Aminomethyl polystyrene resin (0.200 g, 0.745 mmolg-1) was functionalised 
according to general procedure 1 then Fmoc deprotected and amino acid coupled with 
Fmoc-Asp(OAll)-OH according to general procedure 2. The resin (1 eq) was swollen 
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in DCM for 5 min then washed with DCM (× 3). Diester dihydrotetrazine 45 (31.2 mg, 
0.156 mmol, 1.05 eq) in DCM (1.49 mL) and DDQ (0.101 g, 0.447 mmol, 3 eq) were 
added to the resin at rt. The resin was agitated for 4 h then filtered before washing with 
DMF (× 3), DCM (× 3), methanol (× 3) and diethyl ether (× 3). The linker was cleaved 
according to general procedure 3 to give crude product. The crude product was purified 
by flash column chromatography eluting with DCM up to DCM:methanol (49:1) to 
give diester pyridazine derivatised Fmoc-Asp-NH2 84 as a colourless solid (80.0 mg, 
95 %): Rf (DCM:MeOH, 19:1) 0.32; mp 119-120 °C; IR (neat, cm-1) 3336 (N-H), 
1725 (C=O), 1685 (C=O), 1250 (C-O), 1138 (C-O); 1H NMR δ (500 MHz, CDCl3) 
8.35 (1H, ArH), 7.73 (2H, d, J 7.6 Hz, ArH), 7.56 (2H, d, J 7.4 Hz, ArH), 7.40-7.36 
(2H, m, ArH), 7.31-7.27 (2H, m, ArH), 6.35 (1H, br s, RCONH2), 6.03 (1H, br s, 
RCONH2), 5.70 (1H, br s, ROCONHR), 5.62-5.51 (2H, m, ArCH2OCOR), 4.65 (1H, 
br s, ROCONHCHRCONH2), 4.51-4.47 (2H, m, RCH2OCONHR), 4.20-4.18 (1H, m, 
R3CH), 4.07 (6H, s, CO2CH3), 3.16 (1H, d, J 15.7 Hz, RCH2R), 2.87 (1H, dd, J 15.7 
and 3.4 Hz, RCH2R); 13C NMR δ (125 MHz, CDCl3) 172.4 (1C, ROCONHR), 171.3 
(1C, ROCOR), 164.5 (1C, ArCO2R), 164.0 (1C, ArCO2R), 156.3 (1C, RCONH2), 
152.5 (1C, Ar), 150.2 (1C, Ar), 143.7 (1C, Ar), 143.6 (1C, Ar), 141.5 (2C, Ar), 139.1 
(1C, Ar), 128.0 (2C, ArH), 127.3 (1C, ArH), 127.2 (1C, ArH), 126.0 (1C, ArH), 125.1 
(1C, ArH), 125.0 (1C, ArH), 120.2 (2C, ArH), 67.3 (1C, RCH2OCONHR), 61.9 (1C, 
ArCH2OCOR), 53.8 (2C, CO2CH3), 50.9 (1C, ROCONHCHRCONH2), 47.4 (1C, 
R3CH), 35.7 (1C, RCH2R); m/z (ESI+, MeCN) 563.0 ([M+H]
+, 23 %), 585.0 
([M+Na]+, 34 %), 233.1 (28), 102.3 (100); HRMS (ESI+, MeCN) [M+H]+ found 
563.1777 (C28H27N4O9 requires 563.1778); HPLC (column 3, method A, ELSD, 















Aminomethyl polystyrene resin (0.200 g, 0.745 mmolg-1) was functionalised 
according to general procedure 1 then Fmoc deprotected and amino acid coupled with 
Fmoc-Glu(OAll)-OH according to general procedure 2. The resin (1 eq) was swollen 
in DCM for 5 min then washed with DCM (× 3). Diester dihydrotetrazine 45 (31.2 mg, 
0.156 mmol, 1.05 eq) in DCM (1.49 mL) and DDQ (0.101 g, 0.447 mmol, 3 eq) were 
added to the resin at rt. The resin was agitated for 4 h then filtered before washing with 
DMF (× 3), DCM (× 3), methanol (× 3) and diethyl ether (× 3). The linker was cleaved 
according to general procedure 3 to give crude product. The crude product was purified 
by flash column chromatography eluting with DCM up to DCM:methanol (49:1) to 
give diester pyridazine derivatised Fmoc-Glu-NH2 85 as a colourless solid (74.0 mg, 
86 %): Rf (DCM:MeOH, 19:1) 0.36; mp 124-125 °C; IR (neat, cm-1) 1724 (C=O), 
1692 (C=O), 1666 (C=O), 1257 (C-O), 1232 (C-O), 1137 (C-O); 1H NMR δ (500 
MHz, CDCl3) 8.29 (1H, ArH), 7.74-7.72 (2H, m, ArH), 7.56 (2H, d, J 7.3 Hz, ArH), 
7.39-7.35 (2H, m, ArH), 7.31-7.27 (2H, m, ArH), 6.31 (1H, br s, RCONH2), 5.74 (1H, 
br s, RCONH2), 5.65 (1H, br s, ROCONHR), 5.57-5.50 (2H, m, ArCH2OCOR), 4.41 
(2H, br d, J 5.9 Hz, RCH2OCONHR), 4.32 (1H, m, ROCONHCHRCONH2), 4.20-
4.17 (1H, m, R3CH), 4.07 (3H, s, CO2CH3), 4.03 (3H, s, CO2CH3), 2.74-2.53 (2H, m, 
RCH2R), 2.30-1.92 (2H, m, RCH2R); 13C NMR δ (125 MHz, CDCl3) 173.3 (1C, 
ROCONHR), 172.6 (1C, ROCOR), 164.5 (1C, ArCO2R), 164.1 (1C, ArCO2R), 156.5 
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(1C, RCONH2), 152.4 (1C, Ar), 150.4 (1C, Ar), 143.8 (2C, Ar), 141.4 (2C, Ar), 139.4 
(1C, Ar), 127.9 (2C, ArH), 127.2 (2C, ArH), 126.0 (1C, ArH), 125.2 (1C, ArH), 125.1 
(1C, ArH), 120.2 (2C, ArH), 67.2 (1C, RCH2OCONHR), 61.6 (1C, ArCH2OCOR), 
53.8 (2C, CO2CH3), 53.5 (1C, ROCONHCHRCONH2), 47.3 (1C, R3CH), 30.1 (1C, 
RCH2R), 28.2 (1C, RCH2R); m/z (ESI+, MeCN) 577.2 ([M+H]
+, 32 %), 599.2 
([M+Na]+, 52 %), 102.3 (100); HRMS (ESI+, MeCN) [M+H]+ found 577.1915 







Acetic acid (8.59 mL, 0.150 mol, 1.05 eq) was added to a stirring solution of 5,5-
dimethyl-1,3-cyclohexanedione (20.0 g, 0.143 mol, 1 eq), DMAP (18.3 g, 0.150 mol, 
1.05 eq) and EDC (28.8 g, 0.150 mol, 1.05 eq) in DMF (300 mL) at rt. The reaction 
mixture was stirred for 1 d before the solvent was removed under reduced pressure. 
The residue was dissolved in ethyl acetate (200 mL) and washed with hydrochloric 
acid (3 × 200 mL, 1 M aq) and water (3 × 200 mL) then dried over anhydrous sodium 
sulfate before the solvent was removed under reduced pressure to give Dde-OH 88 as 
a yellow solid (20.9 g, 80 %): Rf (EtOAc:hexane, 1:9) 0.21; mp 34-36 °C; IR (neat, 
cm-1) 1658 (C=O); 1H NMR δ (500 MHz, CDCl3) 2.61 (3H, s, RCOHCH3), 2.53 (2H, 
s, RCH2COR), 2.36 (2H, s, RCH2COR), 1.08 (6H, s, RCH3); 13C NMR δ (125 MHz, 
CDCl3) 202.6 (1C, RCOR), 198.1 (1C, RCOR), 195.4 (1C, RCOHCH3), 112.5 (1C, 
RCOCRCOR), 52.6 (1C, RCH2COR), 47.1 (1C, RCH2COR), 30.8 (1C, R4C), 28.7 
(1C, RCOHCH3), 28.3 (2C, RCH3); m/z (ESI+, DCM) 183.1 ([M+H]
+, 17 %), 205.1 
([M+Na]+, 17 %), 163.1 (96), 141.1 (35); HPLC (column 2, method A, ELSD, MeCN) 










DIPEA (9.57 mL, 54.9 mmol, 1.5 eq) and Dde-OH 88 (10.0 g, 54.9 mmol, 1.5 eq) 
were added to a stirring solution of Fmoc-Lys-OH hydrochloride (14.8 g, 36.6 mmol, 
1 eq) in methanol (350 mL) at rt. The reaction mixture was stirred overnight before 
the solvent was removed under reduced pressure. The residue was dissolved in ethyl 
acetate (250 mL) and washed with potassium bisulfate solution (250 mL, 1 M aq), 
hydrochloric acid (250 mL, 1 M aq) and water (250 mL) then dried over anhydrous 
sodium sulfate before the solvent was removed under reduced pressure to give crude 
product. The crude product was purified by flash column chromatography eluting with 
ethyl acetate:hexane (1:3) and ethyl acetate:methanol (9:1) to give impure product. 
The impure product was triturated in ethyl acetate:hexane (1:4) then dissolved in 
DCM:methanol (7:3) before the solvent was removed under reduced pressure to give 
Fmoc-Lys(Dde)-OH 89 as a colourless solid (14.4 g, 74 %): Rf (EtOAc:MeOH, 9:1) 
0.65; mp 88-90 °C, literature 76-78 °C;126 IR (neat, cm-1) 3293 (N-H), 1714 (C=O), 
1620 (C=C); 1H NMR δ (500 MHz, CDCl3) 13.32 (1H, br s, RCNHRCH3), 7.74 (2H, 
d, J 7.6 Hz, ArH), 7.60-7.56 (2H, m, ArH), 7.37 (2H, t, J 7.5 Hz, ArH), 7.29-7.26 (2H, 
m, ArH), 5.81 (1H, d, J 8.1 Hz, ROCONHR), 4.37-4.35 (1H, m, 
ROCONHCHRCO2H), 4.34 (2H, d, J 7.2 Hz, RCH2OCONHR), 4.19 (1H, t, J 7.2 Hz, 
R3CH), 3.40-3.33 (2H, m, RNHCH2R), 2.54 (3H, s, RCNHRCH3), 2.35 (4H, s, 
RCH2COR), 2.01-1.95 (1H, m, RCH2R), 1.84-1.66 (3H, m, RCH2R), 1.63-1.46 (2H, 
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m, RCH2R), 1.00 (6H, s, RCH3); 13C NMR δ (125 MHz, CDCl3) 198.4 (2C, RCOR), 
174.7 (1C, ROCONHR), 174.2 (1C, RCNHRCH3), 156.3 (1C, RCO2H), 144.0 (1C, 
Ar), 143.9 (1C, Ar), 141.4 (2C, Ar), 127.8 (2C, ArH), 127.2 (2C, ArH), 125.3 (2C, 
ArH), 120.1 (2C, ArH), 108.0 (1C, RCOCRCOR), 67.2 (1C, RCH2OCONHR), 53.6 
(1C, ROCONHCHRCO2H), 52.6 (2C, RCH2COR), 47.3 (1C, R3CH), 43.4 (1C, 
RNHCH2R), 32.1 (1C, RCH2R), 30.3 (1C, R4C), 28.5 (1C, RCH2R), 28.3 (2C, RCH3), 
22.6 (1C, RCH2R), 18.3 (1C, RCNHRCH3); m/z (ESI+, MeCN) 533.3 ([M+H]
+, 100 
%), 555.3 ([M+Na]+, 8 %); HPLC (column 2, method A, ELSD, MeCN) tR 7.43 min. 







endo-BCN-OH 60 (44.0 mg, 0.293 mmol, 1.05 eq) was added slowly to a stirring 
solution of 3,6-di-2-pyridyl-1,2,4,5-tetrazine (65.9 mg, 0.279 mmol, 1 eq) in DCM 
(2.79 mL) at rt. The reaction mixture was stirred for 2 h before the solvent was 
removed under reduced pressure to give crude product. The crude product was purified 
by flash column chromatography eluting with DCM up to DCM:methanol (49:1) to 
give endo-dipyridyl tricyclopyridazine alcohol 93 as a colourless solid (94.0 mg, 94 
%): Rf (DCM:MeOH, 19:1) 0.08; mp 223-224 °C; IR (neat, cm-1) 3305 (O-H), 1034 
(C-O); 1H NMR δ (500 MHz, CDCl3) 8.72-8.71 (2H, m, ArH), 7.95-7.94 (2H, m, 
ArH), 7.87 (2H, td, J 7.7 and 1.8 Hz, ArH), 7.37 (2H, ddd, J 7.5, 4.9 and 1.2 Hz, ArH), 
3.74 (2H, d, J 7.4 Hz, RCH2OH), 3.17-2.90 (4H, m, ArCH2R), 2.45-2.31 (2H, m, 
RCH2CHR2), 1.63 (2H, br s, RCH2CHR2), 1.48 (1H, br s, ROH), 1.18-0.99 (3H, m, 
R3CH and R2CHCH2OH); 13C NMR δ (125 MHz, CDCl3) 159.2 (2C, Ar), 157.2 (2C, 
Ar), 148.8 (2C, ArH), 142.3 (2C, Ar), 136.9 (2C, ArH), 125.1 (2C, ArH), 123.3 (2C, 
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ArH), 59.7 (1C, RCH2OH), 27.9 (2C, ArCH2R), 24.4 (2C, RCH2CHR2), 22.8 (2C, 
R3CH), 19.7 (1C, R2CHCH2OH); m/z (ESI+, MeCN) 359.2 ([M+H]
+, 74 %), 717.3 
([2M+H]+, 5 %), 739.2 ([2M+Na]+, 19 %), 317.2 (91), 102.2 (100); HPLC (column 2, 













Appendix 2. Unsuccessful synthesis of resin-bound diester dihydrotetrazine derivatised H-Gly-OH 
A7. Reagents and reaction conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 
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45 min; b) i) piperidine in DMF, rt, 5 min; ii) Fmoc-Gly-OH (3 eq), oxyma (3 eq), DIC (3 eq), DMF, 




Appendix 3. Unsuccessful synthesis of resin-bound diester dihydrotetrazine derivatised H-Gly-OH 
A7. Reagents and reaction conditions a) Rink amide linker (3 eq), oxyma (3 eq), DIC (3 eq), DMF, rt, 
45 min; b) i) piperidine in DMF, rt, 5 min; ii) Fmoc-Gly-OH (3 eq), oxyma (3 eq), DIC (3 eq), DMF, 
rt, 45 min; c) i) piperidine in DMF, rt, 5 min; ii) dicarboxylic acid dihydrotetrazine 48 (3 eq), oxyma 




Appendix 4. 1,2,4,5-Tetrazine selection for the qualitative stability study of a library of 1,2,4,5-
tetrazines and the qualitative screening studies of the iedDA reactions of a library of 1,2,4,5-tetrazines 

















Appendix 5. Dienophile selection for the qualitative screening studies of the iedDA reactions of a 





rt 60 °C 
I 46 < 30 minb < 30 minb 
II 92 > 2 d > 2 d 
III A8 > 2 d > 2 d 
IV A9 > 2 d > 2 d 
V A10 > 2 d > 2 d 
VI A11 > 2 d > 2 d 
 
Appendix 6. Qualitative stability study of a library of 1,2,4,5-tetrazines. a 0.1 M in DMF. b Complete 
















Entry Dienophile 1,2,4,5-Tetrazinea,b 
92 A8 A9 A10 A11 
I endo-60 < 15 min < 15 min > 2 d > 2 d > 2 d 
II (Z)-exo-A12 < 30 min < 1 d > 2 d > 2 d > 2 d 
III (±)-(Z)-61 < 1 d > 2 d > 2 d > 2 d > 2 d 
IV 62 > 2 d > 2 d > 2 d > 2 d > 2 d 
V 63 > 2 d > 2 d > 2 d > 2 d > 2 d 
VI A13 > 2 d > 2 d > 2 d > 2 d > 2 d 
VII A14 > 2 d > 2 d > 2 d > 2 d > 2 d 
VIII A15 > 2 d > 2 d > 2 d > 2 d > 2 d 
IX A16 > 2 d > 2 d > 2 d > 2 d > 2 d 
 
Appendix 7. Qualitative screening study of the iedDA reactions of a library of 1,2,4,5-tetrazines with 
a library of dienophiles at rt. Reagents and reaction conditions a) dienophile (1.05 eq), DMF, rt, 2 d. a 
0.1 M. b Complete iedDA reaction of a 1,2,4,5-tetrazine with a dienophile was indicated by a colour 
change from purple to colourless. 
 
 
Entry Dienophile 1,2,4,5-Tetrazinea 
92 A8 A9 A10 A11 
I endo-60 < 15 min < 15 min > 2 d > 2 d > 2 d 
II (Z)-exo-A12 < 30 min < 4 h > 2 d > 2 d > 2 d 
III (±)-(Z)-61 < 4 h > 2 d > 2 d > 2 d > 2 d 
IV 62 < 8 h > 2 d > 2 d > 2 d > 2 d 
V 63 < 1 d > 2 d > 2 d > 2 d > 2 d 
VI A13 > 2 d > 2 d > 2 d > 2 d > 2 d 
VII A14 > 2 d > 2 d > 2 d > 2 d > 2 d 
VIII A15 > 2 d > 2 d > 2 d > 2 d > 2 d 
IX A16 > 2 d > 2 d > 2 d > 2 d > 2 d 
 
Appendix 8. Qualitative screening study of the iedDA reactions of a library of 1,2,4,5-tetrazines with 
a library of dienophiles at 60 °C. Reagents and reaction conditions a) dienophile (1.05 eq), DMF, 60 
°C, 2 d. a 0.1 M. b Complete iedDA reaction of a 1,2,4,5-tetrazine with a dienophile was indicated by a 
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